Therapeutic targeting of microRNAs: current status and future challenges

Key Points MicroRNAs (miRNAs) have important roles in many aspects of human diseases, and their targeted inhibition may have substantial therapeutic impact. Inhibition of miRNAs can be achieved through a variety of methods and chemically modified antisense oligonucleotides (anti-miRs) have shown the...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Nature reviews. Drug discovery Ročník 13; číslo 8; s. 622 - 638
Hlavní autori:	Li, Zhonghan, Rana, Tariq M.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 01.08.2014 Nature Publishing Group
Predmet:	631/154/51/391/2310 631/337/384/331 692/699/255 692/699/67 692/699/75 Animals Antisense RNA Biomedicine Biotechnology Cancer Research Drug Delivery Systems Drug Discovery Genetic regulation Genetic research Humans Medicinal Chemistry MicroRNAs - biosynthesis MicroRNAs - drug effects MicroRNAs - physiology Molecular Medicine Pharmacology/Toxicology Properties review-article RNA Interference - drug effects RNA Interference - physiology
ISSN:	1474-1776, 1474-1784, 1474-1784
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Key Points MicroRNAs (miRNAs) have important roles in many aspects of human diseases, and their targeted inhibition may have substantial therapeutic impact. Inhibition of miRNAs can be achieved through a variety of methods and chemically modified antisense oligonucleotides (anti-miRs) have shown the most prominent effects. Targeted delivery of anti-miRs is crucial to achieve intended therapeutic effects, and further efforts are warranted to develop more efficient delivery systems. MicroRNAs (miRNAs) — 21- to 23-nucleotide single-stranded RNAs that regulate gene expression — have roles in numerous diseases, and are therefore attractive therapeutic targets. Li and Rana discuss strategies in the design of miRNA-targeting oligonucleotides with increased efficacy and improved in vivo delivery characteristics, and highlight some of the challenges that lie ahead in the clinical development of these therapeutics. MicroRNAs (miRNAs) are evolutionarily conserved small non-coding RNAs that have crucial roles in regulating gene expression. Increasing evidence supports a role for miRNAs in many human diseases, including cancer and autoimmune disorders. The function of miRNAs can be efficiently and specifically inhibited by chemically modified antisense oligonucleotides, supporting their potential as targets for the development of novel therapies for several diseases. In this Review we summarize our current knowledge of the design and performance of chemically modified miRNA-targeting antisense oligonucleotides, discuss various in vivo delivery strategies and analyse ongoing challenges to ensure the specificity and efficacy of therapeutic oligonucleotides in vivo . Finally, we review current progress on the clinical development of miRNA-targeting therapeutics.
AbstractList	MicroRNAs (miRNAs) are evolutionarily conserved small non-coding RNAs that have crucial roles in regulating gene expression. Increasing evidence supports a role for miRNAs in many human diseases, including cancer and autoimmune disorders. The function of miRNAs can be efficiently and specifically inhibited by chemically modified antisense oligonucleotides, supporting their potential as targets for the development of novel therapies for several diseases. In this Review we summarize our current knowledge of the design and performance of chemically modified miRNA-targeting antisense oligonucleotides, discuss various in vivo delivery strategies and analyse ongoing challenges to ensure the specificity and efficacy of therapeutic oligonucleotides in vivo. Finally, we review current progress on the clinical development of miRNA-targeting therapeutics. MicroRNAs (miRNAs) are evolutionarily conserved small non-coding RNAs that have crucial roles in regulating gene expression. Increasing evidence supports a role for miRNAs in many human diseases, including cancer and autoimmune disorders. The function of miRNAs can be efficiently and specifically inhibited by chemically modified anti-sense oligonucleotides, supporting their potential as targets for the development of novel therapies for several diseases. In this Review we summarize our current knowledge of the design and performance of chemically modified miRNA-targeting anti-sense oligonucleotides, discuss various in vivo delivery strategies and analyse ongoing challenges to ensure the specificity and efficacy of therapeutic oligonucleotides in vivo. Finally, we review current progress on the clinical development of miRNA-targeting therapeutics. Key Points MicroRNAs (miRNAs) have important roles in many aspects of human diseases, and their targeted inhibition may have substantial therapeutic impact. Inhibition of miRNAs can be achieved through a variety of methods and chemically modified antisense oligonucleotides (anti-miRs) have shown the most prominent effects. Targeted delivery of anti-miRs is crucial to achieve intended therapeutic effects, and further efforts are warranted to develop more efficient delivery systems. MicroRNAs (miRNAs) — 21- to 23-nucleotide single-stranded RNAs that regulate gene expression — have roles in numerous diseases, and are therefore attractive therapeutic targets. Li and Rana discuss strategies in the design of miRNA-targeting oligonucleotides with increased efficacy and improved in vivo delivery characteristics, and highlight some of the challenges that lie ahead in the clinical development of these therapeutics. MicroRNAs (miRNAs) are evolutionarily conserved small non-coding RNAs that have crucial roles in regulating gene expression. Increasing evidence supports a role for miRNAs in many human diseases, including cancer and autoimmune disorders. The function of miRNAs can be efficiently and specifically inhibited by chemically modified antisense oligonucleotides, supporting their potential as targets for the development of novel therapies for several diseases. In this Review we summarize our current knowledge of the design and performance of chemically modified miRNA-targeting antisense oligonucleotides, discuss various in vivo delivery strategies and analyse ongoing challenges to ensure the specificity and efficacy of therapeutic oligonucleotides in vivo . Finally, we review current progress on the clinical development of miRNA-targeting therapeutics. MicroRNAs (miRNAs) are evolutionarily conserved small non-coding RNAs that have crucial roles in regulating gene expression. Increasing evidence supports a role for miRNAs in many human diseases, including cancer and autoimmune disorders. The function of miRNAs can be efficiently and specifically inhibited by chemically modified antisense oligonucleotides, supporting their potential as targets for the development of novel therapies for several diseases. In this Review we summarize our current knowledge of the design and performance of chemically modified miRNA-targeting antisense oligonucleotides, discuss various in vivo delivery strategies and analyse ongoing challenges to ensure the specificity and efficacy of therapeutic oligonucleotides in vivo. Finally, we review current progress on the clinical development of miRNA-targeting therapeutics.MicroRNAs (miRNAs) are evolutionarily conserved small non-coding RNAs that have crucial roles in regulating gene expression. Increasing evidence supports a role for miRNAs in many human diseases, including cancer and autoimmune disorders. The function of miRNAs can be efficiently and specifically inhibited by chemically modified antisense oligonucleotides, supporting their potential as targets for the development of novel therapies for several diseases. In this Review we summarize our current knowledge of the design and performance of chemically modified miRNA-targeting antisense oligonucleotides, discuss various in vivo delivery strategies and analyse ongoing challenges to ensure the specificity and efficacy of therapeutic oligonucleotides in vivo. Finally, we review current progress on the clinical development of miRNA-targeting therapeutics.
Audience	Academic
Author	Li, Zhonghan Rana, Tariq M.
Author_xml	– sequence: 1 givenname: Zhonghan surname: Li fullname: Li, Zhonghan organization: Drug Safety, Research & Development, Pfizer – sequence: 2 givenname: Tariq M. surname: Rana fullname: Rana, Tariq M. email: trana@ucsd.edu organization: Program for RNA Biology, Sanford–Burnham Medical Research Institute, Department of Pediatrics, University of California San Diego School of Medicine
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/25011539$$D View this record in MEDLINE/PubMed
BookMark	eNptkVtrHCEYhqWkNIeG_oMy0IvmZlK_UceZ3i2hTQohgZJci6ufG8Oss_VwkX9fl2x62BYvFHl81ec9JgdhDkjIO6DnQNnwKUTLmRhfkSPgkrcgB37way37Q3Kc0iOl0IPs3pDDTlAAwcYjcnX3gFFvsGRvmqzjCrMPq2Z2zdqbOH-_WaTPjSkxYshNyjqX1OhgG1dyidiYBz1NGFaY3pLXTk8JT3fzCbn_-uXu4qq9vr38drG4bo2gQ25h7FAz6GwvUI9uNB1aLZztreV6KS3yznXIwaLjzC0BmWFySaXonJOSc3ZCzp5zN3H-UTBltfbJ4DTpgHNJCoQACkMv-4p-2EMf5xJDfd2WotCNnI2_qZWeUPng5hy12YaqBRsAeC8kq9T5f6g6LFZRtQzn6_5fB97vLi_LNVq1iX6t45N6UV-B9hmomlOK6JTx1a-fQ032kwKqttWqXbWV_7jHv0T-S-4UpUrUbuIf_95DfwI_5K7U
CitedBy_id	crossref_primary_10_1016_j_omtn_2023_04_018 crossref_primary_10_1080_10837450_2019_1623252 crossref_primary_10_1016_j_mad_2017_05_004 crossref_primary_10_1038_s41419_019_2079_y crossref_primary_10_1002_ange_201512002 crossref_primary_10_1016_j_omtn_2017_06_009 crossref_primary_10_1016_j_cbi_2019_01_011 crossref_primary_10_1016_j_gpb_2018_03_002 crossref_primary_10_3390_cells9010137 crossref_primary_10_1016_j_archoralbio_2021_105336 crossref_primary_10_1016_j_yjmcc_2022_02_007 crossref_primary_10_1016_j_bone_2021_115968 crossref_primary_10_1093_carcin_bgv085 crossref_primary_10_1016_j_virusres_2024_199396 crossref_primary_10_1016_j_bbrc_2019_11_019 crossref_primary_10_1016_j_ymthe_2018_05_002 crossref_primary_10_3389_fcell_2025_1569101 crossref_primary_10_1016_j_omtn_2018_08_020 crossref_primary_10_1159_000477235 crossref_primary_10_3390_ijms17101752 crossref_primary_10_3389_fonc_2017_00331 crossref_primary_10_1038_nrd_2016_117 crossref_primary_10_1177_1535370219890303 crossref_primary_10_1111_liv_14276 crossref_primary_10_1016_j_drudis_2017_01_014 crossref_primary_10_1016_j_tox_2020_152635 crossref_primary_10_1042_BJ20150821 crossref_primary_10_1186_s12951_024_02561_x crossref_primary_10_1016_j_yexcr_2024_114234 crossref_primary_10_1155_2020_4947381 crossref_primary_10_3389_fcell_2025_1593241 crossref_primary_10_1007_s40618_023_02059_7 crossref_primary_10_1016_j_pbiomolbio_2016_09_008 crossref_primary_10_3389_fchem_2018_00238 crossref_primary_10_1007_s00018_015_1939_6 crossref_primary_10_3389_fimmu_2014_00513 crossref_primary_10_3390_mps4010010 crossref_primary_10_2217_nnm_2017_0345 crossref_primary_10_1093_nar_gkz798 crossref_primary_10_2147_OTT_S249662 crossref_primary_10_1016_j_biocel_2017_01_020 crossref_primary_10_1016_j_biomaterials_2018_11_035 crossref_primary_10_1016_j_mam_2018_07_003 crossref_primary_10_1002_hep_31569 crossref_primary_10_3390_livers2030017 crossref_primary_10_1007_s11883_022_01007_9 crossref_primary_10_1152_ajprenal_00254_2019 crossref_primary_10_3389_fcimb_2017_00095 crossref_primary_10_3390_ijms19041217 crossref_primary_10_1016_j_arr_2023_102090 crossref_primary_10_1146_annurev_cancerbio_050216_034443 crossref_primary_10_1016_j_humgen_2025_201456 crossref_primary_10_1007_s13277_016_4960_y crossref_primary_10_1016_j_pharmthera_2016_09_001 crossref_primary_10_3390_cancers13194983 crossref_primary_10_1016_j_prp_2021_153588 crossref_primary_10_1038_s41419_022_05075_2 crossref_primary_10_1111_fcp_12915 crossref_primary_10_1007_s11033_018_4358_6 crossref_primary_10_1002_adma_202419651 crossref_primary_10_4103_1673_5374_276323 crossref_primary_10_1002_mgg3_473 crossref_primary_10_1186_s12943_022_01528_6 crossref_primary_10_1080_08830185_2017_1347649 crossref_primary_10_1016_j_semcancer_2017_02_004 crossref_primary_10_1038_nbt_3765 crossref_primary_10_3389_fcvm_2023_1183181 crossref_primary_10_1038_bjc_2015_201 crossref_primary_10_1155_2018_9740357 crossref_primary_10_1007_s00432_024_06046_0 crossref_primary_10_1016_j_ijbiomac_2025_145025 crossref_primary_10_1016_j_jconrel_2019_07_006 crossref_primary_10_1093_neuonc_nox152 crossref_primary_10_1016_j_phrs_2023_106870 crossref_primary_10_1080_00207454_2020_1806836 crossref_primary_10_1016_j_omtn_2018_09_015 crossref_primary_10_1093_nar_gkac864 crossref_primary_10_1016_j_drudis_2017_09_018 crossref_primary_10_1038_s41392_018_0006_9 crossref_primary_10_1084_jem_20211366 crossref_primary_10_1186_s11658_022_00317_9 crossref_primary_10_1007_s12640_020_00236_7 crossref_primary_10_1038_nmat4497 crossref_primary_10_1016_j_jacc_2020_02_041 crossref_primary_10_1016_j_addr_2014_09_003 crossref_primary_10_1016_j_biopha_2016_09_087 crossref_primary_10_1186_s12990_015_0045_y crossref_primary_10_1016_j_bios_2020_112757 crossref_primary_10_1007_s10928_015_9406_4 crossref_primary_10_1016_j_bbalip_2016_01_010 crossref_primary_10_2217_bmm_14_108 crossref_primary_10_2337_db16_0147 crossref_primary_10_4251_wjgo_v9_i7_268 crossref_primary_10_1002_cbf_3079 crossref_primary_10_1038_s41598_023_39537_0 crossref_primary_10_1038_srep22884 crossref_primary_10_1093_nar_gkz492 crossref_primary_10_3389_fgene_2014_00472 crossref_primary_10_1038_s41467_022_34433_z crossref_primary_10_1002_adma_201504564 crossref_primary_10_1016_j_tcb_2014_11_004 crossref_primary_10_3390_pharmaceutics15020320 crossref_primary_10_1016_j_talanta_2025_128173 crossref_primary_10_1016_j_vph_2018_06_011 crossref_primary_10_3389_fcell_2020_00812 crossref_primary_10_1002_anse_202400009 crossref_primary_10_1016_j_jpha_2025_101339 crossref_primary_10_1186_s40001_025_02561_z crossref_primary_10_3390_cancers12123831 crossref_primary_10_3390_cells10113097 crossref_primary_10_1016_j_cbpa_2014_10_024 crossref_primary_10_1373_clinchem_2015_242800 crossref_primary_10_1093_cvr_cvz183 crossref_primary_10_1093_nar_gku1156 crossref_primary_10_1038_s41598_018_20053_5 crossref_primary_10_1158_2326_6066_CIR_15_0084 crossref_primary_10_1371_journal_pone_0192562 crossref_primary_10_1667_RR14784_1 crossref_primary_10_1016_j_kint_2017_05_034 crossref_primary_10_3389_fcell_2020_00818 crossref_primary_10_1007_s12031_020_01600_0 crossref_primary_10_1093_advances_nmy059 crossref_primary_10_1095_biolreprod_115_131334 crossref_primary_10_1155_2015_716816 crossref_primary_10_3390_biom12040496 crossref_primary_10_3762_bjoc_17_116 crossref_primary_10_1167_iovs_18_24878 crossref_primary_10_1038_s41598_019_48359_y crossref_primary_10_1139_cjpp_2018_0430 crossref_primary_10_3390_nu14235081 crossref_primary_10_1210_endocr_bqaa053 crossref_primary_10_1016_j_coviro_2015_03_007 crossref_primary_10_1186_s13148_021_01107_4 crossref_primary_10_1093_nar_gku1367 crossref_primary_10_1007_s10456_017_9545_x crossref_primary_10_1038_s42003_024_06555_1 crossref_primary_10_1371_journal_pone_0188085 crossref_primary_10_1586_14737140_2016_1121107 crossref_primary_10_3389_fonc_2024_1469319 crossref_primary_10_2217_epi_2022_0277 crossref_primary_10_4103_1673_5374_332154 crossref_primary_10_1016_j_actbio_2021_07_027 crossref_primary_10_1016_j_phrs_2023_106855 crossref_primary_10_1016_j_cej_2021_129951 crossref_primary_10_1007_s11011_019_00485_2 crossref_primary_10_1073_pnas_1917531117 crossref_primary_10_1039_D5RA04137F crossref_primary_10_1093_nar_gkad705 crossref_primary_10_1038_s41420_022_01012_6 crossref_primary_10_3389_fgene_2014_00317 crossref_primary_10_1002_smtd_202402154 crossref_primary_10_1186_s12920_015_0109_x crossref_primary_10_1016_j_genrep_2022_101676 crossref_primary_10_1080_17425255_2018_1472237 crossref_primary_10_1016_j_cca_2018_01_036 crossref_primary_10_1002_advs_201700324 crossref_primary_10_3390_polym14194195 crossref_primary_10_1016_j_actbio_2021_08_041 crossref_primary_10_1016_j_ymthe_2019_08_005 crossref_primary_10_1038_leu_2014_351 crossref_primary_10_1371_journal_pone_0204860 crossref_primary_10_3390_pharmaceutics15041216 crossref_primary_10_4331_wjbc_v8_i1_45 crossref_primary_10_1007_s11523_020_00717_x crossref_primary_10_1038_s41598_021_93666_y crossref_primary_10_1007_s10620_020_06518_6 crossref_primary_10_1039_C9RA05176G crossref_primary_10_1016_j_jconrel_2016_05_054 crossref_primary_10_1016_j_transproceed_2022_10_044 crossref_primary_10_1038_s41388_017_0088_9 crossref_primary_10_3389_fimmu_2020_01214 crossref_primary_10_1155_2020_2052396 crossref_primary_10_3390_foods13213507 crossref_primary_10_1016_j_omtn_2022_08_020 crossref_primary_10_1016_j_talanta_2018_02_036 crossref_primary_10_1002_ctm2_602 crossref_primary_10_1016_j_bmc_2022_117148 crossref_primary_10_3389_fneur_2020_00663 crossref_primary_10_3390_ijms222111309 crossref_primary_10_1080_17474124_2016_1251309 crossref_primary_10_1007_s13204_022_02701_5 crossref_primary_10_1016_j_asems_2025_100158 crossref_primary_10_1007_s11033_022_07620_w crossref_primary_10_1016_j_csbj_2021_01_018 crossref_primary_10_3390_ijms17060864 crossref_primary_10_1016_j_cmet_2015_08_018 crossref_primary_10_1007_s10735_020_09950_0 crossref_primary_10_1007_s12035_018_0951_x crossref_primary_10_1016_j_molmed_2016_12_007 crossref_primary_10_3390_ijms161226138 crossref_primary_10_1016_j_ymthe_2019_02_010 crossref_primary_10_3892_mmr_2018_8530 crossref_primary_10_1016_j_bbamcr_2023_119523 crossref_primary_10_1016_j_ecoenv_2020_111876 crossref_primary_10_1016_j_molmet_2019_06_009 crossref_primary_10_1111_imr_12450 crossref_primary_10_1016_j_colsurfb_2023_113533 crossref_primary_10_1038_s42003_017_0011_5 crossref_primary_10_1007_s11926_016_0604_x crossref_primary_10_1038_s41419_018_0760_1 crossref_primary_10_1007_s00439_019_02046_0 crossref_primary_10_3389_fmolb_2022_883060 crossref_primary_10_1016_j_taap_2021_115637 crossref_primary_10_1134_S1068162024605986 crossref_primary_10_1096_fj_202100282R crossref_primary_10_3389_fnut_2023_1221438 crossref_primary_10_1111_jcmm_14644 crossref_primary_10_1159_000530160 crossref_primary_10_2217_epi_2015_0016 crossref_primary_10_1002_hep4_1029 crossref_primary_10_1073_pnas_1818522116 crossref_primary_10_1016_j_ymthe_2019_09_001 crossref_primary_10_1097_BOR_0000000000000420 crossref_primary_10_1007_s00277_015_2369_0 crossref_primary_10_1016_j_phrs_2025_107822 crossref_primary_10_1016_j_coph_2015_05_004 crossref_primary_10_1038_s41388_020_01486_7 crossref_primary_10_1002_jcp_30195 crossref_primary_10_1038_s41598_017_10500_0 crossref_primary_10_1042_BCJ20170079 crossref_primary_10_22270_jddt_v15i8_7336 crossref_primary_10_1002_1873_3468_12749 crossref_primary_10_3389_fphar_2020_00191 crossref_primary_10_1186_s12931_022_02024_7 crossref_primary_10_1039_C5CC07478A crossref_primary_10_3389_fphys_2020_00793 crossref_primary_10_1111_liv_13687 crossref_primary_10_1165_rcmb_2014_0166TR crossref_primary_10_52976_vansaglik_952243 crossref_primary_10_1186_s13287_015_0221_z crossref_primary_10_1016_j_addr_2015_05_001 crossref_primary_10_3389_fimmu_2019_01335 crossref_primary_10_3390_pharmaceutics14030669 crossref_primary_10_1158_0008_5472_CAN_17_0530 crossref_primary_10_1016_j_omtn_2022_08_036 crossref_primary_10_1016_j_jinorgbio_2015_05_001 crossref_primary_10_3389_fgene_2018_00439 crossref_primary_10_3389_fcell_2021_650431 crossref_primary_10_3389_finsc_2025_1583941 crossref_primary_10_3389_fped_2022_1053965 crossref_primary_10_1007_s12016_016_8589_9 crossref_primary_10_1186_s13046_023_02635_y crossref_primary_10_3389_fgene_2018_00311 crossref_primary_10_1097_MOL_0000000000000281 crossref_primary_10_1186_s13058_017_0918_2 crossref_primary_10_1186_s12957_020_02088_z crossref_primary_10_2147_JHC_S380237 crossref_primary_10_1016_j_biomaterials_2021_120907 crossref_primary_10_7554_eLife_79768 crossref_primary_10_1080_14737140_2022_2114457 crossref_primary_10_3390_ijms17081357 crossref_primary_10_3389_fonc_2024_1410656 crossref_primary_10_1038_s41419_018_0313_7 crossref_primary_10_1016_j_biopha_2018_11_057 crossref_primary_10_1089_nat_2019_0820 crossref_primary_10_1111_cas_14317 crossref_primary_10_3892_mmr_2019_10245 crossref_primary_10_1016_j_bcp_2015_11_021 crossref_primary_10_3233_JAD_160203 crossref_primary_10_3389_fonc_2025_1517995 crossref_primary_10_1038_s41598_024_58882_2 crossref_primary_10_1111_jop_12785 crossref_primary_10_1093_nar_gkv1221 crossref_primary_10_1038_s42003_021_02822_7 crossref_primary_10_1002_advs_201903290 crossref_primary_10_1038_s41419_018_1178_5 crossref_primary_10_3390_genes9020074 crossref_primary_10_3390_molecules22050782 crossref_primary_10_1186_s40164_023_00451_w crossref_primary_10_1016_j_jad_2018_06_034 crossref_primary_10_1097_MD_0000000000025753 crossref_primary_10_63500_mv_v26_48 crossref_primary_10_1177_09733698241229803 crossref_primary_10_1186_s11658_021_00281_w crossref_primary_10_1021_jacs_6b06965 crossref_primary_10_1155_2020_8837941 crossref_primary_10_3390_pharmaceutics13040530 crossref_primary_10_1007_s00393_018_0477_7 crossref_primary_10_1111_jop_12650 crossref_primary_10_3389_fonc_2018_00631 crossref_primary_10_3390_molecules25204701 crossref_primary_10_3892_etm_2019_7286 crossref_primary_10_1042_BSR20181051 crossref_primary_10_1016_j_plipres_2016_03_006 crossref_primary_10_1007_s00204_017_1974_1 crossref_primary_10_3390_genes16060647 crossref_primary_10_1016_j_pneurobio_2016_11_001 crossref_primary_10_1038_nrd_2016_246 crossref_primary_10_3390_ijms21186486 crossref_primary_10_1111_jcmm_15776 crossref_primary_10_1038_s41467_017_01359_w crossref_primary_10_3389_fphys_2018_00953 crossref_primary_10_1016_S1872_2040_18_61099_0 crossref_primary_10_3389_fonc_2021_704664 crossref_primary_10_3892_etm_2021_10808 crossref_primary_10_3389_fphys_2020_00738 crossref_primary_10_1186_s12931_020_01491_0 crossref_primary_10_1113_JP280917 crossref_primary_10_3389_fimmu_2017_00104 crossref_primary_10_3389_fonc_2024_1385632 crossref_primary_10_1080_17474124_2020_1820321 crossref_primary_10_1002_bies_201500054 crossref_primary_10_3389_fonc_2023_1191070 crossref_primary_10_1002_cctc_202401550 crossref_primary_10_2217_pme_2016_0090 crossref_primary_10_1007_s00441_020_03246_1 crossref_primary_10_3389_fonc_2021_752817 crossref_primary_10_3390_cancers16213701 crossref_primary_10_1177_2040620719866081 crossref_primary_10_1016_j_ijpharm_2019_06_020 crossref_primary_10_3390_biom12081070 crossref_primary_10_1155_2014_920134 crossref_primary_10_1080_17474086_2018_1447921 crossref_primary_10_1177_15593258211001255 crossref_primary_10_3389_fphar_2019_00451 crossref_primary_10_1016_j_neulet_2016_07_059 crossref_primary_10_26599_OSHM_2025_9610013 crossref_primary_10_1016_j_bbadis_2025_167731 crossref_primary_10_1016_j_molimm_2018_07_022 crossref_primary_10_3390_biomedicines10123060 crossref_primary_10_1038_srep27105 crossref_primary_10_1016_j_bcp_2017_07_008 crossref_primary_10_7717_peerj_15912 crossref_primary_10_1080_21541264_2023_2294623 crossref_primary_10_1007_s11892_020_01325_9 crossref_primary_10_1007_s10456_021_09778_6 crossref_primary_10_1186_s13045_019_0748_z crossref_primary_10_2147_CMAR_S285113 crossref_primary_10_3390_epigenomes6040037 crossref_primary_10_3390_ijms20215299 crossref_primary_10_2174_0115672018306882240618093152 crossref_primary_10_1016_j_ejpb_2024_114203 crossref_primary_10_1016_j_jconrel_2016_06_020 crossref_primary_10_1096_fj_202401124RRR crossref_primary_10_1109_TNB_2022_3170530 crossref_primary_10_3390_ijms22126538 crossref_primary_10_1002_ange_202305227 crossref_primary_10_1515_bams_2017_0023 crossref_primary_10_3892_ol_2024_14798 crossref_primary_10_1016_j_healun_2017_03_019 crossref_primary_10_1097_MOL_0000000000000336 crossref_primary_10_3390_nano13162360 crossref_primary_10_1371_journal_pone_0142708 crossref_primary_10_3748_wjg_v22_i2_557 crossref_primary_10_2217_epi_2020_0439 crossref_primary_10_1016_j_clon_2016_04_048 crossref_primary_10_1016_j_pbiomolbio_2019_11_009 crossref_primary_10_3389_fmolb_2017_00038 crossref_primary_10_3390_ijms23094493 crossref_primary_10_1016_j_bmcl_2015_07_016 crossref_primary_10_1016_j_beem_2016_10_001 crossref_primary_10_1016_j_jconrel_2016_06_006 crossref_primary_10_1371_journal_ppat_1006508 crossref_primary_10_1002_advs_202411210 crossref_primary_10_1093_carcin_bgab124 crossref_primary_10_1016_j_mcp_2019_101470 crossref_primary_10_1002_cbic_201500537 crossref_primary_10_2217_epi_2016_0058 crossref_primary_10_1016_j_tet_2021_132261 crossref_primary_10_1016_j_gene_2024_149011 crossref_primary_10_1007_s11154_023_09866_6 crossref_primary_10_1002_jbt_70252 crossref_primary_10_1007_s00535_019_01627_0 crossref_primary_10_1016_j_lfs_2025_123832 crossref_primary_10_1155_2015_739469 crossref_primary_10_1038_s41416_020_0758_1 crossref_primary_10_1038_cdd_2017_87 crossref_primary_10_1016_j_lfs_2022_120761 crossref_primary_10_1002_ddr_21344 crossref_primary_10_1007_s12519_019_00265_z crossref_primary_10_1159_000371736 crossref_primary_10_1007_s13346_020_00721_8 crossref_primary_10_3390_ijms17071120 crossref_primary_10_1038_srep43604 crossref_primary_10_1039_C8CC02332H crossref_primary_10_1007_s11010_024_05164_0 crossref_primary_10_1177_1535370218822988 crossref_primary_10_1186_s12864_016_2620_7 crossref_primary_10_1016_j_addr_2017_10_008 crossref_primary_10_1038_s41598_021_88922_0 crossref_primary_10_1016_j_xcrm_2025_102248 crossref_primary_10_1016_j_drudis_2017_04_020 crossref_primary_10_1016_j_prp_2023_154511 crossref_primary_10_1038_s41583_018_0001_8 crossref_primary_10_1016_j_jgg_2017_04_003 crossref_primary_10_1016_j_jnutbio_2020_108376 crossref_primary_10_1016_j_cotox_2017_10_010 crossref_primary_10_1155_2022_3101900 crossref_primary_10_3390_v11060540 crossref_primary_10_1158_0008_5472_CAN_19_1807 crossref_primary_10_3390_ijms20163884 crossref_primary_10_1155_2019_6782653 crossref_primary_10_4155_fmc_15_107 crossref_primary_10_3389_fimmu_2023_1129298 crossref_primary_10_3390_pharmaceutics14020342 crossref_primary_10_1016_j_addr_2014_12_006 crossref_primary_10_1080_08830185_2017_1281272 crossref_primary_10_1016_j_molmed_2015_07_005 crossref_primary_10_3390_ijms19113378 crossref_primary_10_1111_bph_16409 crossref_primary_10_3389_fchem_2023_1335330 crossref_primary_10_1002_1878_0261_12085 crossref_primary_10_1016_j_bmc_2022_116803 crossref_primary_10_3390_ijms222111596 crossref_primary_10_1016_j_prp_2019_01_038 crossref_primary_10_1007_s10544_018_0298_0 crossref_primary_10_1515_biol_2020_0058 crossref_primary_10_1002_adtp_202500082 crossref_primary_10_1016_j_ncrna_2017_06_001 crossref_primary_10_1038_s41388_020_1360_y crossref_primary_10_1016_j_yexcr_2020_111939 crossref_primary_10_3390_genes13030425 crossref_primary_10_3390_jpm13111586 crossref_primary_10_1155_2019_5179048 crossref_primary_10_1016_j_lfs_2019_02_059 crossref_primary_10_1016_j_biochi_2017_09_014 crossref_primary_10_1093_nar_gkx1239 crossref_primary_10_3390_ijms22010028 crossref_primary_10_1080_14779072_2016_1176528 crossref_primary_10_1074_jbc_REV119_006860 crossref_primary_10_1111_cpr_12963 crossref_primary_10_1007_s11626_019_00417_5 crossref_primary_10_1016_j_bmc_2015_07_062 crossref_primary_10_1016_j_intimp_2016_09_011 crossref_primary_10_1177_1559325820936906 crossref_primary_10_1038_onc_2017_269 crossref_primary_10_1002_jcb_29364 crossref_primary_10_1016_j_biopha_2024_116899 crossref_primary_10_1002_cbic_202100184 crossref_primary_10_1007_s13346_020_00779_4 crossref_primary_10_1016_j_ab_2017_09_007 crossref_primary_10_1038_nri_2016_40 crossref_primary_10_1111_jcmm_16376 crossref_primary_10_3389_fimmu_2017_01062 crossref_primary_10_1007_s00403_025_04043_y crossref_primary_10_1007_s12035_016_9940_0 crossref_primary_10_1371_journal_pone_0210633 crossref_primary_10_1089_nat_2017_0663 crossref_primary_10_1038_srep14577 crossref_primary_10_1038_srep37082 crossref_primary_10_1002_anie_202305227 crossref_primary_10_3390_ncrna5020035 crossref_primary_10_1152_jn_00936_2016 crossref_primary_10_1002_prot_24810 crossref_primary_10_1016_j_ajpath_2016_10_017 crossref_primary_10_1002_art_39446 crossref_primary_10_1021_acscentsci_4c01152 crossref_primary_10_1007_s12033_017_0034_7 crossref_primary_10_1007_s00774_023_01433_y crossref_primary_10_1016_j_imbio_2016_11_006 crossref_primary_10_1097_TA_0000000000003350 crossref_primary_10_3389_fimmu_2018_01729 crossref_primary_10_1038_s41419_019_1423_6 crossref_primary_10_3390_ijms160816833 crossref_primary_10_1007_s11033_018_4352_z crossref_primary_10_1158_1078_0432_CCR_15_2173 crossref_primary_10_1002_chem_201505094 crossref_primary_10_1002_cnma_201500036 crossref_primary_10_1016_j_neulet_2017_01_017 crossref_primary_10_3390_ijms222312765 crossref_primary_10_1002_adtp_202100040 crossref_primary_10_1113_EP088399 crossref_primary_10_2147_DMSO_S247062 crossref_primary_10_3389_fcell_2020_00143 crossref_primary_10_1038_srep40131 crossref_primary_10_1016_j_heliyon_2024_e39489 crossref_primary_10_1007_s00018_015_1887_1 crossref_primary_10_1016_j_cellsig_2017_10_007 crossref_primary_10_3389_fonc_2016_00003 crossref_primary_10_1038_s41598_021_03229_4 crossref_primary_10_1080_08830185_2017_1284212 crossref_primary_10_1097_MD_0000000000016538 crossref_primary_10_3390_cancers17132183 crossref_primary_10_2119_molmed_2016_00136 crossref_primary_10_1016_j_arr_2025_102805 crossref_primary_10_1038_s41598_018_29633_x crossref_primary_10_1093_nar_gkab1256 crossref_primary_10_2174_1381612826666200316151720 crossref_primary_10_1523_JNEUROSCI_0851_16_2016 crossref_primary_10_1038_onc_2016_485 crossref_primary_10_1016_j_canlet_2014_09_034 crossref_primary_10_3390_cells12131694 crossref_primary_10_3892_ijo_2025_5769 crossref_primary_10_3389_fonc_2022_987609 crossref_primary_10_1186_s12943_019_1069_0 crossref_primary_10_3390_cells9092061 crossref_primary_10_1002_cbf_4116 crossref_primary_10_1016_j_chemphyslip_2019_104837 crossref_primary_10_1186_s13287_020_01966_3 crossref_primary_10_1038_s41419_018_1281_7 crossref_primary_10_1038_s41467_017_02449_5 crossref_primary_10_3390_pharmaceutics15071833 crossref_primary_10_1016_j_phrs_2024_107083 crossref_primary_10_1186_s12935_023_03133_z crossref_primary_10_1111_febs_13026 crossref_primary_10_3389_fcell_2021_758240 crossref_primary_10_1093_ckj_sfac219 crossref_primary_10_1155_2020_2198308 crossref_primary_10_1016_j_ejmech_2023_115500 crossref_primary_10_1007_s00018_017_2531_z crossref_primary_10_3390_pharmaceutics17070930 crossref_primary_10_1016_j_virol_2016_12_009 crossref_primary_10_1186_s12967_021_03226_1 crossref_primary_10_1016_j_ejphar_2014_11_046 crossref_primary_10_2217_nnm_2017_0054 crossref_primary_10_1182_blood_2018882290 crossref_primary_10_1016_j_cld_2015_06_009 crossref_primary_10_1016_j_canlet_2019_10_017 crossref_primary_10_1042_BST20170037 crossref_primary_10_1111_cbdd_12634 crossref_primary_10_2147_DDDT_S288859 crossref_primary_10_1007_s12038_022_00288_1 crossref_primary_10_3390_life13081696 crossref_primary_10_1515_biol_2021_0028 crossref_primary_10_3390_ijms24065737 crossref_primary_10_1039_C9RA04898G crossref_primary_10_1007_s11033_018_4511_2 crossref_primary_10_1007_s40495_014_0009_3 crossref_primary_10_1039_C9RA01374A crossref_primary_10_1111_apm_12828 crossref_primary_10_1007_s13273_024_00468_0 crossref_primary_10_3762_bjoc_13_134 crossref_primary_10_1007_s11883_017_0699_1 crossref_primary_10_1038_nrendo_2015_25 crossref_primary_10_1016_j_omtn_2019_01_003 crossref_primary_10_1038_s41419_018_0274_x crossref_primary_10_1186_s13287_019_1146_8 crossref_primary_10_1371_journal_pone_0301540 crossref_primary_10_1016_j_bios_2025_117910 crossref_primary_10_3389_fonc_2022_1047177 crossref_primary_10_1002_tox_24199 crossref_primary_10_3389_fonc_2020_00906 crossref_primary_10_1016_j_biopha_2019_109313 crossref_primary_10_1038_srep25108 crossref_primary_10_3389_fcell_2025_1600103 crossref_primary_10_1038_s41598_024_63582_y crossref_primary_10_1161_ATVBAHA_115_306506 crossref_primary_10_3390_microorganisms7090359 crossref_primary_10_1155_2017_3720128 crossref_primary_10_3390_ijms24031878 crossref_primary_10_1186_s12929_019_0558_1 crossref_primary_10_1002_ijc_30912 crossref_primary_10_1002_wrna_1461 crossref_primary_10_1038_s41598_018_22577_2 crossref_primary_10_1002_cbic_202000287 crossref_primary_10_1016_j_pharmthera_2016_07_006 crossref_primary_10_1007_s10495_017_1367_1 crossref_primary_10_1186_s12929_018_0422_8 crossref_primary_10_1631_jzus_B2300305 crossref_primary_10_1016_j_jconrel_2014_12_030 crossref_primary_10_1016_j_drudis_2017_10_009 crossref_primary_10_1080_13543784_2021_1879792 crossref_primary_10_1016_j_ejphar_2020_173529 crossref_primary_10_1016_j_chembiol_2017_10_009 crossref_primary_10_1007_s11523_017_0476_7 crossref_primary_10_3389_fcvm_2023_1128708 crossref_primary_10_1039_C6CC02894B crossref_primary_10_1159_000514543 crossref_primary_10_1016_j_biopha_2019_109302 crossref_primary_10_1038_s41467_017_01737_4 crossref_primary_10_1038_s41573_025_01237_x crossref_primary_10_1016_j_csbj_2016_12_006 crossref_primary_10_1002_anie_201512002 crossref_primary_10_3389_fmolb_2021_743013 crossref_primary_10_1002_wrna_1477 crossref_primary_10_1016_j_abb_2022_109139 crossref_primary_10_1007_s00066_023_02064_y crossref_primary_10_1016_j_biopha_2018_12_106 crossref_primary_10_1002_jcp_29538 crossref_primary_10_1016_j_gene_2018_09_008 crossref_primary_10_1039_C9NR08154B crossref_primary_10_1155_2017_7354260 crossref_primary_10_1111_apm_12514 crossref_primary_10_1161_ATVBAHA_116_308905 crossref_primary_10_1038_s41467_018_05023_9 crossref_primary_10_1080_10641963_2018_1510941 crossref_primary_10_1038_modpathol_2015_149 crossref_primary_10_1016_j_pharmthera_2016_11_004 crossref_primary_10_1038_s41388_020_01579_3 crossref_primary_10_3390_ijms21239285 crossref_primary_10_1002_wrna_1409 crossref_primary_10_3389_fgene_2022_931797 crossref_primary_10_3390_diagnostics10121102 crossref_primary_10_1097_CCO_0000000000000253 crossref_primary_10_1016_j_critrevonc_2017_06_007 crossref_primary_10_3389_fnano_2022_911063 crossref_primary_10_3390_ijms20205176 crossref_primary_10_1155_2019_7304895 crossref_primary_10_1016_j_phrs_2024_107299 crossref_primary_10_1080_15384101_2020_1856497 crossref_primary_10_1016_j_molmed_2020_01_010 crossref_primary_10_1080_07391102_2021_1873861 crossref_primary_10_1089_hum_2016_171 crossref_primary_10_1080_17425247_2016_1214567 crossref_primary_10_1002_chem_201903240 crossref_primary_10_3389_fmolb_2015_00031 crossref_primary_10_3389_fnmol_2019_00031 crossref_primary_10_1182_blood_2016_10_697698 crossref_primary_10_1007_s13277_016_5405_3 crossref_primary_10_1016_j_clinbiochem_2016_08_010 crossref_primary_10_1371_journal_pgen_1006139 crossref_primary_10_1002_hep_30301 crossref_primary_10_1186_s13578_020_00382_7 crossref_primary_10_1016_j_actbio_2018_05_049 crossref_primary_10_3389_fimmu_2022_951798 crossref_primary_10_1007_s10495_022_01773_6 crossref_primary_10_1016_j_biopha_2019_109350 crossref_primary_10_3389_fphar_2021_747223 crossref_primary_10_1016_j_bmcl_2017_01_023 crossref_primary_10_1002_ddr_21267 crossref_primary_10_1016_j_gendis_2025_101853 crossref_primary_10_1093_nar_gkz638 crossref_primary_10_1016_j_jconrel_2020_08_028 crossref_primary_10_3390_ijms22115414 crossref_primary_10_1002_chem_202004495 crossref_primary_10_1016_j_ejphar_2019_172659 crossref_primary_10_1021_jacs_6b01625 crossref_primary_10_1002_ddr_21270 crossref_primary_10_1111_nan_12765 crossref_primary_10_3389_fimmu_2025_1567459 crossref_primary_10_3389_fimmu_2021_703936 crossref_primary_10_3390_cancers11122019 crossref_primary_10_3390_cancers13215361 crossref_primary_10_1002_ddr_21274 crossref_primary_10_1016_j_imbio_2017_05_003 crossref_primary_10_1016_j_jconrel_2015_08_011 crossref_primary_10_3390_ijms161024895 crossref_primary_10_1016_j_yexcr_2019_111591 crossref_primary_10_3390_pharmaceutics14020258 crossref_primary_10_1080_17474086_2018_1517041 crossref_primary_10_3390_epigenomes1030024 crossref_primary_10_1016_j_healun_2016_03_018 crossref_primary_10_1016_j_omtn_2019_09_029 crossref_primary_10_1097_WNR_0000000000001912 crossref_primary_10_1007_s11523_017_0478_5 crossref_primary_10_1016_j_prrv_2016_12_002 crossref_primary_10_1021_jacs_6b08369 crossref_primary_10_1007_s12032_023_02212_5 crossref_primary_10_1016_j_ymthe_2024_12_043 crossref_primary_10_1016_j_biochi_2017_03_003 crossref_primary_10_1002_chem_201705695 crossref_primary_10_1124_dmd_120_000008 crossref_primary_10_1159_000444677 crossref_primary_10_1007_s12975_022_01071_y crossref_primary_10_1038_s41531_024_00791_2 crossref_primary_10_1109_ACCESS_2020_3004512 crossref_primary_10_1586_17446651_2015_996131 crossref_primary_10_3390_jcm14062054 crossref_primary_10_1002_ddr_21260 crossref_primary_10_1038_s41598_017_15388_4 crossref_primary_10_1186_s12879_021_06775_4 crossref_primary_10_4155_fmc_2016_0018 crossref_primary_10_3389_fnmol_2018_00189 crossref_primary_10_1186_s12964_017_0209_7 crossref_primary_10_1038_s41386_020_00861_y crossref_primary_10_1016_j_nano_2016_02_017 crossref_primary_10_3390_cells10092246 crossref_primary_10_1080_17425247_2019_1617693
Cites_doi	10.1038/nature09267 10.1038/35888 10.1021/cb7000582 10.1038/nature04263 10.1016/j.cmet.2006.01.005 10.1016/j.ymeth.2007.11.001 10.1016/j.gene.2005.12.031 10.1038/nature04688 10.4161/cc.7.6.5834 10.1038/nature03868 10.1161/CIRCRESAHA.111.244442 10.1002/path.2806 10.1158/0008-5472.CAN-08-1305 10.1021/ja910275u 10.1038/nrd2614 10.1016/j.cell.2011.09.029 10.1146/annurev.biochem.67.1.99 10.1038/sj.onc.1210856 10.1038/nbt1101 10.1038/ncb2024 10.1101/gad.1424106 10.1073/pnas.0712321105 10.1371/journal.pone.0020391 10.1042/BJ20080599 10.1038/nature03120 10.1021/jm00059a007 10.1126/science.1149859 10.1038/nature02871 10.1161/CIRCRESAHA.111.248880 10.1038/nchembio.939 10.1016/j.tips.2009.08.004 10.1016/0014-5793(93)81427-2 10.1016/j.cell.2005.01.014 10.1039/a708608c 10.1038/nbt.1564 10.1089/nat.2011.0298 10.1016/j.addr.2012.09.033 10.1073/pnas.1016152108 10.1016/0092-8674(93)90530-4 10.1038/nnano.2012.73 10.1038/onc.2008.178 10.1517/17425250902877680 10.1038/nrd3179 10.1021/ja9822862 10.1038/nrg2843 10.1002/hep.21663 10.1016/j.cell.2007.10.054 10.1073/pnas.0404432101 10.1016/j.cell.2008.10.053 10.1261/rna.1591709 10.1038/nbt.1618 10.1261/rna.5103703 10.1126/science.1093616 10.1242/dev.006486 10.1016/j.molcel.2009.08.020 10.1038/nature04303 10.1021/ar200253u 10.1261/rna.5235104 10.1038/ng.317 10.1038/nm1191 10.1158/0008-5472.CAN-11-1144 10.1002/anie.200801555 10.1371/journal.pbio.0000060 10.1016/j.cell.2008.06.034 10.1093/nar/gkl183 10.1053/j.gastro.2007.05.022 10.1158/0008-5472.CAN-05-0137 10.1074/jbc.M611393200 10.1016/j.cell.2012.08.002 10.1126/science.1115079 10.1038/35002607 10.1007/s11095-010-0156-0 10.1371/journal.pbio.0050203 10.1038/nrg2634 10.1038/nchembio839 10.1016/j.cell.2005.07.031 10.1038/nri2708 10.1016/j.cell.2010.01.007 10.1038/emboj.2011.2 10.1161/CIRCULATIONAHA.111.030932 10.1038/ncb1333 10.1016/j.addr.2012.09.011 10.1002/emmm.201100209 10.1038/nbt1339 10.1038/nature10112 10.1371/journal.pmed.0030096 10.1016/S0092-8674(04)00045-5 10.1016/j.molcel.2006.01.031 10.1261/rna.2414110 10.1074/jbc.M707224200 10.1126/science.1157396 10.1038/nature08956 10.1016/j.addr.2012.09.006 10.1093/nar/gkg707 10.1038/nbt0713-577 10.1093/nar/gnh140 10.1158/0008-5472.CAN-07-1083 10.1016/S0167-4781(99)00138-4 10.1126/science.1113329 10.1016/j.cell.2009.12.023 10.1038/nmeth1079 10.1073/pnas.0907904107 10.1158/1078-0432.CCR-09-0092 10.1006/dbio.1999.9523 10.1016/j.cell.2011.09.028 10.1073/pnas.0703820104 10.1371/journal.pbio.0040210 10.1016/j.cell.2011.09.032 10.1038/nature06765 10.1016/j.cell.2012.05.003 10.1016/j.cell.2009.06.044 10.1038/nbt1402 10.1038/ni.1863 10.1038/nature07511 10.1093/nar/gkm1113 10.1038/mt.2008.14 10.1038/gt.2011.100 10.1073/pnas.0307323101 10.1038/35078107 10.1038/ni.2648 10.1016/0092-8674(93)90529-Y 10.1021/ja012288d 10.4049/jimmunol.172.11.6545 10.1128/MCB.05776-11 10.1038/nrd3864 10.1093/toxsci/kft278 10.1126/science.1137999 10.1186/1471-2105-8-69 10.1038/nbt.2612 10.1038/mtna.2013.46 10.1073/pnas.1208863110 10.1093/nar/26.9.2224 10.1016/j.molcel.2008.09.014 10.1126/science.1178178 10.1146/annurev.pharmtox.010909.105654 10.1093/nar/gkl1071 10.1158/0008-5472.CAN-04-0637 10.1371/journal.pcbi.0010013 10.1016/j.cell.2004.12.035 10.1038/sj.onc.1210425 10.1126/science.1139089 10.1038/nsmb.1405 10.1073/pnas.0701458104 10.1073/pnas.0510565103 10.1038/nature11134 10.1371/journal.pbio.0020098 10.1038/nbt1081 10.1089/ard.1994.4.201 10.1038/nature06783 10.1089/oli.1.1997.7.503 10.1089/nat.2011.0332 10.1038/ng.786 10.1016/j.cell.2008.02.019 10.1093/nar/23.11.2019 10.1038/mt.2010.85 10.1016/S1097-2765(02)00652-4 10.1038/nbt1122 10.1089/nat.2012.0366 10.1038/onc.2011.193 10.1002/hep.20702 10.1016/j.cell.2009.01.002 10.1158/0008-5472.CAN-05-0565 10.1038/nature03121 10.1093/nar/gkq1307 10.1083/jcb.201208082 10.1056/NEJMoa073108 10.1126/science.1093620 10.1038/nsmb.2580
ContentType	Journal Article
Copyright	Springer Nature Limited 2014 COPYRIGHT 2014 Nature Publishing Group Copyright Nature Publishing Group Aug 2014
Copyright_xml	– notice: Springer Nature Limited 2014 – notice: COPYRIGHT 2014 Nature Publishing Group – notice: Copyright Nature Publishing Group Aug 2014
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8
DOI	10.1038/nrd4359
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) Medical Database Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	ProQuest One Academic Middle East (New) MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology
EISSN	1474-1784
EndPage	638
ExternalDocumentID	3389798531 A381146573 25011539 10_1038_nrd4359
Genre	Journal Article Review Research Support, N.I.H., Extramural
GroupedDBID	--- 0R~ 123 29M 36B 39C 3V. 4.4 53G 70F 7RV 7X7 88E 8AO 8FI 8FJ 8R4 8R5 AAEEF AARCD AAWYQ AAYOK AAYZH AAZLF ABAWZ ABDBF ABJNI ABLJU ABNNU ABUWG ACGFO ACGFS ACMJI ACRPL ACUHS ADBBV ADFRT ADNMO AENEX AFBBN AFKRA AFSHS AGAYW AGGDT AGHTU AHBCP AHMBA AHOSX AHSBF AIBTJ AIYXT ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH ARMCB ASPBG AVWKF AXYYD AZFZN B0M BENPR BKEYQ BKKNO BPHCQ BVXVI CCPQU CS3 DB5 DU5 EAD EAP EBS EE. EJD EMB EMK EMOBN EPL ESX EX3 EXGXG F5P FEDTE FQGFK FSGXE FYUFA HMCUK HVGLF HZ~ IAO IHR INH INR ITC L-9 LGEZI LOTEE M1P MK0 N9A NADUK NAPCQ NNMJJ NXXTH O9- ODYON P2P PQQKQ PROAC PSQYO Q2X RNR RNS RNT RNTTT SHXYY SIXXV SNYQT SOJ SV3 TAOOD TBHMF TDRGL TSG TUS UKHRP WOW ~8M AAYXX ABFSG AFANA AFFHD ALPWD ATHPR CITATION PHGZM PHGZT PJZUB PPXIY ACSTC AEZWR AFHIU AGQPQ AHWEU AIXLP CGR CUY CVF ECM EIF NFIDA NPM 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO
ID	FETCH-LOGICAL-c508t-192ea312d65ea9f9c2eda5fd6dd4ab7de42f2e41def43fb1e3c37b0752ff77443
IEDL.DBID	7RV
ISICitedReferencesCount	879
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000340075500018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1474-1776 1474-1784
IngestDate	Wed Oct 01 17:25:56 EDT 2025 Mon Oct 06 16:56:38 EDT 2025 Tue Nov 11 10:28:44 EST 2025 Tue Nov 04 17:11:33 EST 2025 Mon Jul 21 05:27:48 EDT 2025 Sat Nov 29 03:31:57 EST 2025 Tue Nov 18 22:41:47 EST 2025 Fri Feb 21 02:37:25 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	8
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c508t-192ea312d65ea9f9c2eda5fd6dd4ab7de42f2e41def43fb1e3c37b0752ff77443
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
PMID	25011539
PQID	1550129439
PQPubID	27580
PageCount	17
ParticipantIDs	proquest_miscellaneous_1551018676 proquest_journals_1550129439 gale_infotracmisc_A381146573 gale_infotracacademiconefile_A381146573 pubmed_primary_25011539 crossref_citationtrail_10_1038_nrd4359 crossref_primary_10_1038_nrd4359 springer_journals_10_1038_nrd4359
PublicationCentury	2000
PublicationDate	2014-08-01
PublicationDateYYYYMMDD	2014-08-01
PublicationDate_xml	– month: 08 year: 2014 text: 2014-08-01 day: 01
PublicationDecade	2010
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Nature reviews. Drug discovery
PublicationTitleAbbrev	Nat Rev Drug Discov
PublicationTitleAlternate	Nat Rev Drug Discov
PublicationYear	2014
Publisher	Nature Publishing Group UK Nature Publishing Group
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group
References	Lennox, Behlke (CR13) 2011; 18 Papagiannakopoulos, Shapiro, Kosik (CR45) 2008; 68 Croce (CR146) 2009; 10 Lee (CR102) 2012; 7 Heil (CR115) 2004; 303 Bennett, Swayze (CR119) 2010; 50 Majlessi, Nelson, Becker (CR58) 1998; 26 Meyer (CR167) 2012; 149 Grun, Wang, Langenberger, Gunsalus, Rajewsky (CR41) 2005; 1 Behm-Ansmant (CR37) 2006; 20 Zimmermann (CR88) 2006; 441 Judge (CR116) 2005; 23 Bagga (CR33) 2005; 122 Eulalio, Huntzinger, Izaurralde (CR36) 2008; 15 Cesana (CR50) 2011; 147 Diebold, Kaisho, Hemmi, Akira, Reis e Sousa (CR114) 2004; 303 Davis, Lollo, Freier, Esau (CR72) 2006; 34 Gilleron (CR133) 2013; 31 Park (CR160) 2011; 71 Rigo (CR73) 2012; 8 Petersen, Bondensgaard, Wengel, Jacobsen (CR74) 2002; 124 Esquela-Kerscher (CR143) 2008; 7 Ebert, Sharp (CR48) 2010; 16 Brannon-Peppas, Blanchette (CR130) 2012; 64 Malam, Loizidou, Seifalian (CR94) 2009; 30 Ventura (CR128) 2008; 132 Guo, Ingolia, Weissman, Bartel (CR34) 2010; 466 Manoharan (CR69) 1999; 1489 Kumar, Lee, Shankar, Manjunath (CR93) 2006; 3 Young, Connelly, Grohmann, Deiters (CR53) 2010; 132 Reinhart (CR138) 2000; 403 Han (CR20) 2009; 136 Zeng, Sankala, Zhang, Graves (CR170) 2008; 413 Farazi, Spitzer, Morozov, Tuschl (CR9) 2011; 223 Kumar (CR142) 2008; 105 Montgomery (CR153) 2011; 124 Li, Rana (CR18) 2012; 45 Bartel (CR39) 2009; 136 Hsu, Mitragotri (CR85) 2011; 108 Pineau (CR159) 2010; 107 Ma (CR43) 2010; 12 Davis (CR99) 2010; 464 Singh, Koshkin, Wengel, Nielsen (CR75) 1998; 1998 Ebert, Neilson, Sharp (CR47) 2007; 4 Chan, Krichevsky, Kosik (CR76) 2005; 65 Matsubara (CR127) 2007; 26 Verma, Eckstein (CR56) 1998; 67 Kortylewski (CR84) 2009; 27 Yu (CR66) 2012; 150 Kang (CR129) 2013; 14 van Deutekom (CR109) 2007; 357 Lee, Feinbaum, Ambros (CR27) 1993; 75 Obad (CR80) 2011; 43 Yu (CR144) 2007; 131 Jurk (CR118) 2011; 21 Fire (CR1) 1998; 391 Bartel (CR3) 2004; 116 Yao (CR106) 2012; 4 Morrissey (CR87) 2005; 41 Eiring (CR163) 2010; 140 Soutschek (CR65) 2004; 432 Tay (CR49) 2011; 147 Chu, Rana (CR38) 2006; 4 Jopling, Yi, Lancaster, Lemon, Sarnow (CR134) 2005; 309 Kakiuchi-Kiyota (CR125) 2013; 138 Meng (CR147) 2007; 133 Iorio, Croce (CR136) 2012; 4 Pillai (CR29) 2005; 309 Zhu, Si, Wu, Mo (CR148) 2007; 282 Klattenhoff, Theurkauf (CR5) 2008; 135 Morrissey (CR86) 2005; 23 Esau (CR70) 2006; 3 Johnson (CR140) 2005; 120 Kawasaki (CR71) 1993; 36 Gregory (CR22) 2004; 432 Brigger, Dubernet, Couvreur (CR131) 2012; 64 Bumcrot, Manoharan, Koteliansky, Sah (CR14) 2006; 2 Esau (CR12) 2008; 44 Lamond, Sproat (CR55) 1993; 325 Song (CR103) 2005; 23 Porrello (CR156) 2013; 110 Porrello (CR154) 2011; 109 Kleinman (CR113) 2008; 452 Stark, Brennecke, Russell, Cohen (CR40) 2003; 1 Schiffelers (CR96) 2004; 32 Krol, Loedige, Filipowicz (CR19) 2010; 11 Wightman, Ha, Ruvkun (CR28) 1993; 75 Kloosterman, Lagendijk, Ketting, Moulton, Plasterk (CR108) 2007; 5 Takamizawa (CR139) 2004; 64 Nishina (CR83) 2008; 16 Karreth (CR51) 2011; 147 Stanton (CR124) 2012; 22 Braconi (CR164) 2011; 30 Davis, Chen, Shin (CR95) 2008; 7 Lewis, Burge, Bartel (CR26) 2005; 120 Petersen, Bordeleau, Pelletier, Sharp (CR31) 2006; 21 Hornung (CR117) 2005; 11 Khraiwesh (CR162) 2010; 140 Ambros (CR4) 2004; 431 Johnson (CR46) 2007; 67 Krutzfeldt (CR16) 2005; 438 Elmen (CR79) 2008; 36 Koshkin (CR78) 1998; 120 Heo (CR171) 2008; 32 Olsen, Ambros (CR30) 1999; 216 Lytle, Yario, Steitz (CR32) 2007; 104 Jain (CR132) 2012; 64 Swayze (CR123) 2007; 35 Mayr, Hemann, Bartel (CR141) 2007; 315 Wen (CR105) 2007; 46 Chiu, Rana (CR64) 2003; 9 Meister, Landthaler, Dorsett, Tuschl (CR60) 2004; 10 Volinia (CR145) 2006; 103 Wolfrum (CR82) 2007; 25 Thum (CR67) 2008; 456 Lindow, Kauppinen (CR135) 2012; 199 Zisoulis, Kai, Chang, Pasquinelli (CR166) 2012; 486 Akinc (CR89) 2008; 26 O'Connell, Rao, Chaudhuri, Baltimore (CR11) 2010; 10 Melo (CR24) 2009; 41 Su, Baigude, McCarroll, Rana (CR101) 2011; 39 Ma (CR68) 2010; 28 Asangani (CR149) 2008; 27 Fornari (CR157) 2008; 27 Ghildiyal (CR6) 2008; 320 Triboulet, Chang, Lapierre, Gregory (CR21) 2009; 15 Palliser (CR92) 2006; 439 Gramantieri (CR158) 2009; 15 Taulli, Loretelli, Pandolfi (CR165) 2013; 20 Lanford (CR15) 2010; 327 Lal (CR107) 2009; 35 Tang, Li, Tucker, Ramratnam (CR168) 2011; 6 Akinc (CR90) 2010; 18 Gaidatzis, van Nimwegen, Hausser, Zavolan (CR42) 2007; 8 Boutla, Delidakis, Tabler (CR54) 2003; 31 Li, Yang, Nakashima, Rana (CR44) 2011; 30 Garzon, Marcucci, Croce (CR126) 2010; 9 Hutvagner, Simard, Mello, Zamore (CR59) 2004; 2 Frankel (CR150) 2008; 283 van Rooij (CR152) 2007; 316 Hullinger (CR155) 2012; 110 Galbraith, Hobson, Giclas, Schechter, Agrawal (CR121) 1994; 4 van Rooij, Olson (CR10) 2012; 11 Cummins (CR57) 1995; 23 Hammond, Wood (CR110) 2010; 12 Calin (CR7) 2004; 101 Kumar (CR104) 2008; 134 Wu (CR169) 2011; 31 Chendrimada (CR23) 2005; 436 Gumireddy (CR52) 2008; 47 Hildebrandt-Eriksen (CR122) 2012; 22 Peer, Park, Morishita, Carman, Shimaoka (CR91) 2008; 319 Kawai, Akira (CR111) 2010; 11 Paroo, Ye, Chen, Liu (CR25) 2009; 139 Calin (CR8) 2004; 101 Orom, Kauppinen, Lund (CR77) 2006; 372 Elmen (CR17) 2008; 452 Liu (CR35) 2005; 7 Chau (CR151) 2012; 4 Lennox, Owczarzy, Thomas, Walder, Behlke (CR81) 2013; 2 Trajkovski (CR161) 2011; 474 Chiu, Rana (CR63) 2002; 10 Kariko, Bhuyan, Capodici, Weissman (CR112) 2004; 172 Baigude, McCarroll, Yang, Swain, Rana (CR100) 2007; 2 Lennox, Behlke (CR61) 2010; 27 Elbashir (CR2) 2001; 411 Geary (CR62) 2009; 5 Heidel (CR97) 2007; 104 Hu-Lieskovan, Heidel, Bartlett, Davis, Triche (CR98) 2005; 65 Bouchie (CR137) 2013; 31 Henry, Novotny, Leeds, Auletta, Kornbrust (CR120) 1997; 7 ER Porrello (BFnrd4359_CR154) 2011; 109 K Kariko (BFnrd4359_CR112) 2004; 172 RK Jain (BFnrd4359_CR132) 2012; 64 C Wolfrum (BFnrd4359_CR82) 2007; 25 ES Hildebrandt-Eriksen (BFnrd4359_CR122) 2012; 22 RI Gregory (BFnrd4359_CR22) 2004; 432 FA Karreth (BFnrd4359_CR51) 2011; 147 SG Kang (BFnrd4359_CR129) 2013; 14 R Taulli (BFnrd4359_CR165) 2013; 20 C Wu (BFnrd4359_CR169) 2011; 31 JR Lytle (BFnrd4359_CR32) 2007; 104 Z Li (BFnrd4359_CR18) 2012; 45 BJ Reinhart (BFnrd4359_CR138) 2000; 403 AM Kawasaki (BFnrd4359_CR71) 1993; 36 S Davis (BFnrd4359_CR72) 2006; 34 EE Swayze (BFnrd4359_CR123) 2007; 35 J Soutschek (BFnrd4359_CR65) 2004; 432 AA Koshkin (BFnrd4359_CR78) 1998; 120 Z Li (BFnrd4359_CR44) 2011; 30 AM Eiring (BFnrd4359_CR163) 2010; 140 M Trajkovski (BFnrd4359_CR161) 2011; 474 I Heo (BFnrd4359_CR171) 2008; 32 A Stark (BFnrd4359_CR40) 2003; 1 SM Johnson (BFnrd4359_CR140) 2005; 120 J Liu (BFnrd4359_CR35) 2005; 7 J Elmen (BFnrd4359_CR79) 2008; 36 P Pineau (BFnrd4359_CR159) 2010; 107 C Braconi (BFnrd4359_CR164) 2011; 30 R Garzon (BFnrd4359_CR126) 2010; 9 JK Park (BFnrd4359_CR160) 2011; 71 P Kumar (BFnrd4359_CR104) 2008; 134 H Lee (BFnrd4359_CR102) 2012; 7 F Fornari (BFnrd4359_CR157) 2008; 27 WM Galbraith (BFnrd4359_CR121) 1994; 4 D Grun (BFnrd4359_CR41) 2005; 1 DG Zisoulis (BFnrd4359_CR166) 2012; 486 D Gaidatzis (BFnrd4359_CR42) 2007; 8 CC Esau (BFnrd4359_CR12) 2008; 44 T Hsu (BFnrd4359_CR85) 2011; 108 Y Tay (BFnrd4359_CR49) 2011; 147 DV Morrissey (BFnrd4359_CR86) 2005; 23 SS Diebold (BFnrd4359_CR114) 2004; 303 X Tang (BFnrd4359_CR168) 2011; 6 AD Judge (BFnrd4359_CR116) 2005; 23 A Lal (BFnrd4359_CR107) 2009; 35 A Eulalio (BFnrd4359_CR36) 2008; 15 A Boutla (BFnrd4359_CR54) 2003; 31 H Matsubara (BFnrd4359_CR127) 2007; 26 GA Calin (BFnrd4359_CR7) 2004; 101 R Triboulet (BFnrd4359_CR21) 2009; 15 F Yu (BFnrd4359_CR144) 2007; 131 F Rigo (BFnrd4359_CR73) 2012; 8 A Akinc (BFnrd4359_CR89) 2008; 26 G Hutvagner (BFnrd4359_CR59) 2004; 2 SM Hammond (BFnrd4359_CR110) 2010; 12 E van Rooij (BFnrd4359_CR152) 2007; 316 D Palliser (BFnrd4359_CR92) 2006; 439 ME Davis (BFnrd4359_CR99) 2010; 464 RM O'Connell (BFnrd4359_CR11) 2010; 10 J Takamizawa (BFnrd4359_CR139) 2004; 64 KS Singh (BFnrd4359_CR75) 1998; 1998 J Elmen (BFnrd4359_CR17) 2008; 452 CY Chu (BFnrd4359_CR38) 2006; 4 L Ma (BFnrd4359_CR43) 2010; 12 CL Jopling (BFnrd4359_CR134) 2005; 309 T Papagiannakopoulos (BFnrd4359_CR45) 2008; 68 J Krutzfeldt (BFnrd4359_CR16) 2005; 438 KA Lennox (BFnrd4359_CR81) 2013; 2 M Kortylewski (BFnrd4359_CR84) 2009; 27 YD Yao (BFnrd4359_CR106) 2012; 4 M Lindow (BFnrd4359_CR135) 2012; 199 TA Farazi (BFnrd4359_CR9) 2011; 223 SM Elbashir (BFnrd4359_CR2) 2001; 411 A Akinc (BFnrd4359_CR90) 2010; 18 F Heil (BFnrd4359_CR115) 2004; 303 T Kawai (BFnrd4359_CR111) 2010; 11 DP Bartel (BFnrd4359_CR39) 2009; 136 S Bagga (BFnrd4359_CR33) 2005; 122 MS Ebert (BFnrd4359_CR47) 2007; 4 K Gumireddy (BFnrd4359_CR52) 2008; 47 A Esquela-Kerscher (BFnrd4359_CR143) 2008; 7 M Petersen (BFnrd4359_CR74) 2002; 124 AI Lamond (BFnrd4359_CR55) 1993; 325 D Yu (BFnrd4359_CR66) 2012; 150 R Stanton (BFnrd4359_CR124) 2012; 22 J Krol (BFnrd4359_CR19) 2010; 11 S Kakiuchi-Kiyota (BFnrd4359_CR125) 2013; 138 C Esau (BFnrd4359_CR70) 2006; 3 L Gramantieri (BFnrd4359_CR158) 2009; 15 BP Lewis (BFnrd4359_CR26) 2005; 120 J Su (BFnrd4359_CR101) 2011; 39 J Han (BFnrd4359_CR20) 2009; 136 A Bouchie (BFnrd4359_CR137) 2013; 31 S Obad (BFnrd4359_CR80) 2011; 43 KA Lennox (BFnrd4359_CR13) 2011; 18 ME Kleinman (BFnrd4359_CR113) 2008; 452 RS Pillai (BFnrd4359_CR29) 2005; 309 CP Petersen (BFnrd4359_CR31) 2006; 21 JC van Deutekom (BFnrd4359_CR109) 2007; 357 YL Chiu (BFnrd4359_CR64) 2003; 9 H Guo (BFnrd4359_CR34) 2010; 466 GA Calin (BFnrd4359_CR8) 2004; 101 A Fire (BFnrd4359_CR1) 1998; 391 B Khraiwesh (BFnrd4359_CR162) 2010; 140 M Ghildiyal (BFnrd4359_CR6) 2008; 320 S Hu-Lieskovan (BFnrd4359_CR98) 2005; 65 ME Davis (BFnrd4359_CR95) 2008; 7 H Baigude (BFnrd4359_CR100) 2007; 2 S Zhu (BFnrd4359_CR148) 2007; 282 DD Young (BFnrd4359_CR53) 2010; 132 YL Chiu (BFnrd4359_CR63) 2002; 10 E van Rooij (BFnrd4359_CR10) 2012; 11 M Jurk (BFnrd4359_CR118) 2011; 21 SP Henry (BFnrd4359_CR120) 1997; 7 Y Zeng (BFnrd4359_CR170) 2008; 413 PH Olsen (BFnrd4359_CR30) 1999; 216 RM Schiffelers (BFnrd4359_CR96) 2004; 32 E Song (BFnrd4359_CR103) 2005; 23 D Bumcrot (BFnrd4359_CR14) 2006; 2 TG Hullinger (BFnrd4359_CR155) 2012; 110 K Nishina (BFnrd4359_CR83) 2008; 16 RS Geary (BFnrd4359_CR62) 2009; 5 RL Montgomery (BFnrd4359_CR153) 2011; 124 DP Bartel (BFnrd4359_CR3) 2004; 116 UA Orom (BFnrd4359_CR77) 2006; 372 I Behm-Ansmant (BFnrd4359_CR37) 2006; 20 SA Melo (BFnrd4359_CR24) 2009; 41 M Cesana (BFnrd4359_CR50) 2011; 147 V Hornung (BFnrd4359_CR117) 2005; 11 I Brigger (BFnrd4359_CR131) 2012; 64 S Volinia (BFnrd4359_CR145) 2006; 103 LB Frankel (BFnrd4359_CR150) 2008; 283 A Ventura (BFnrd4359_CR128) 2008; 132 F Meng (BFnrd4359_CR147) 2007; 133 S Verma (BFnrd4359_CR56) 1998; 67 MS Kumar (BFnrd4359_CR142) 2008; 105 IA Asangani (BFnrd4359_CR149) 2008; 27 D Peer (BFnrd4359_CR91) 2008; 319 JA Chan (BFnrd4359_CR76) 2005; 65 Z Paroo (BFnrd4359_CR25) 2009; 139 M Majlessi (BFnrd4359_CR58) 1998; 26 MV Iorio (BFnrd4359_CR136) 2012; 4 ER Porrello (BFnrd4359_CR156) 2013; 110 MS Ebert (BFnrd4359_CR48) 2010; 16 BN Chau (BFnrd4359_CR151) 2012; 4 WP Kloosterman (BFnrd4359_CR108) 2007; 5 LL Cummins (BFnrd4359_CR57) 1995; 23 RE Lanford (BFnrd4359_CR15) 2010; 327 CF Bennett (BFnrd4359_CR119) 2010; 50 B Wightman (BFnrd4359_CR28) 1993; 75 P Kumar (BFnrd4359_CR93) 2006; 3 L Brannon-Peppas (BFnrd4359_CR130) 2012; 64 J Gilleron (BFnrd4359_CR133) 2013; 31 KA Lennox (BFnrd4359_CR61) 2010; 27 T Thum (BFnrd4359_CR67) 2008; 456 KD Meyer (BFnrd4359_CR167) 2012; 149 V Ambros (BFnrd4359_CR4) 2004; 431 L Ma (BFnrd4359_CR68) 2010; 28 TS Zimmermann (BFnrd4359_CR88) 2006; 441 JD Heidel (BFnrd4359_CR97) 2007; 104 C Klattenhoff (BFnrd4359_CR5) 2008; 135 G Meister (BFnrd4359_CR60) 2004; 10 DV Morrissey (BFnrd4359_CR87) 2005; 41 CD Johnson (BFnrd4359_CR46) 2007; 67 Y Malam (BFnrd4359_CR94) 2009; 30 WH Wen (BFnrd4359_CR105) 2007; 46 TP Chendrimada (BFnrd4359_CR23) 2005; 436 RC Lee (BFnrd4359_CR27) 1993; 75 C Mayr (BFnrd4359_CR141) 2007; 315 M Manoharan (BFnrd4359_CR69) 1999; 1489 CM Croce (BFnrd4359_CR146) 2009; 10 17379663 - Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21 17182632 - Nucleic Acids Res. 2007;35(2):687-700 15723075 - Nat Med. 2005 Mar;11(3):263-70 17322030 - Science. 2007 Mar 16;315(5818):1576-9 23812097 - Nat Immunol. 2013 Aug;14(8):849-57 14970398 - RNA. 2004 Mar;10(3):544-50 18691745 - Cell. 2008 Aug 22;134(4):577-86 18758474 - Nat Rev Drug Discov. 2008 Sep;7(9):771-82 15024405 - PLoS Biol. 2004 Apr;2(4):E98 15766527 - Cell. 2005 Mar 11;120(5):635-47 20173740 - Nat Cell Biol. 2010 Mar;12 (3):247-56 16081698 - Science. 2005 Sep 2;309(5740):1573-6 14976262 - Science. 2004 Mar 5;303(5663):1526-9 14973191 - Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 17968323 - Oncogene. 2008 Apr 3;27(15):2128-36 16258535 - Nature. 2005 Dec 1;438(7068):685-9 22939619 - Cell. 2012 Aug 31;150(5):895-908 16141076 - Science. 2005 Sep 2;309(5740):1577-81 20211135 - Cell. 2010 Mar 5;140(5):652-65 9361909 - Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):503-10 15538359 - Nature. 2004 Nov 11;432(7014):173-8 22504300 - Nat Chem Biol. 2012 Apr 15;8(6):555-61 21753793 - Gene Ther. 2011 Dec;18(12):1111-20 21212128 - Nucleic Acids Res. 2011 Mar;39(6):e38 20424893 - Pharm Res. 2010 Sep;27(9):1788-99 15372042 - Nature. 2004 Sep 16;431(7006):350-5 20661255 - Nat Rev Genet. 2010 Sep;11(9):597-610 19379126 - Expert Opin Drug Metab Toxicol. 2009 Apr;5(4):381-91 17991735 - J Biol Chem. 2008 Jan 11;283(2):1026-33 18438401 - Nat Biotechnol. 2008 May;26(5):561-9 16461460 - Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 12930946 - Nucleic Acids Res. 2003 Sep 1;31(17):4973-80 21285944 - EMBO J. 2011 Mar 2;30(5):823-34 14744438 - Cell. 2004 Jan 23;116(2):281-97 22659608 - Nat Nanotechnol. 2012 Jun 03;7(6):389-93 15778705 - Nat Biotechnol. 2005 Apr;23(4):457-62 18329372 - Cell. 2008 Mar 7;132(5):875-86 17535905 - Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9667-72 18951094 - Mol Cell. 2008 Oct 24;32(2):276-84 20461061 - Mol Ther. 2010 Jul;18(7):1357-64 18368052 - Nature. 2008 Apr 3;452(7187):591-7 18403677 - Science. 2008 May 23;320(5879):1077-81 17596868 - Hepatology. 2007 Jul;46(1):84-94 15153468 - J Immunol. 2004 Jun 1;172(11):6545-9 22000013 - Cell. 2011 Oct 14;147(2):344-57 19671867 - Clin Cancer Res. 2009 Aug 15;15(16):5073-81 16815998 - Genes Dev. 2006 Jul 15;20(14):1885-98 18829576 - Cancer Res. 2008 Oct 1;68(19):8164-72 17676975 - PLoS Biol. 2007 Aug;5(8):e203 19804757 - Cell. 2009 Oct 2;139(1):112-22 17331257 - BMC Bioinformatics. 2007 Mar 01;8:69 18308936 - Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3903-8 20677099 - Curr Opin Mol Ther. 2010 Aug;12(4):478-86 18032451 - Development. 2008 Jan;135(1):3-9 18083101 - Cell. 2007 Dec 14;131(6):1109-23 16503100 - Gene. 2006 May 10;372:137-41 16756390 - PLoS Biol. 2006 Jul;4(7):e210 18160687 - N Engl J Med. 2007 Dec 27;357(26):2677-86 11373684 - Nature. 2001 May 24;411(6836):494-8 15973356 - Nature. 2005 Aug 4;436(7051):740-4 15908939 - Nat Biotechnol. 2005 Jun;23(6):709-17 23839128 - Nat Biotechnol. 2013 Jul;31(7):577 22000014 - Cell. 2011 Oct 14;147(2):358-69 23248315 - Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):187-92 19749770 - Nat Biotechnol. 2009 Oct;27(10):925-32 22351564 - EMBO Mol Med. 2012 Mar;4(3):143-59 21423181 - Nat Genet. 2011 Mar 20;43(4):371-8 18476811 - Biochem J. 2008 Aug 1;413(3):429-36 16103902 - PLoS Comput Biol. 2005 Jun;1(1):e13 21654750 - Nature. 2011 Jun 08;474(7353):649-53 22304792 - Acc Chem Res. 2012 Jul 17;45(7):1122-31 18344688 - Cell Cycle. 2008 Mar 15;7(6):759-64 17432823 - ACS Chem Biol. 2007 Apr 24;2(4):237-41 10807002 - Biochim Biophys Acta. 1999 Dec 10;1489(1):117-30 7849490 - Antisense Res Dev. 1994 Fall;4(3):201-6 20098459 - Nat Rev Immunol. 2010 Feb;10(2):111-22 8464037 - J Med Chem. 1993 Apr 2;36(7):831-41 17873866 - Nat Biotechnol. 2007 Oct;25(10):1149-57 21903933 - Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15816-21 16690972 - Nucleic Acids Res. 2006 May 11;34(8):2294-304 20885409 - Nat Rev Drug Discov. 2010 Oct;9(10):775-89 21749297 - Nucleic Acid Ther. 2011 Jun;21(3):201-14 21674040 - PLoS One. 2011;6(6):e20391 21125669 - J Pathol. 2011 Jan;223(2):102-15 22000016 - Cell. 2011 Oct 14;147(2):382-95 17681183 - Gastroenterology. 2007 Aug;133(2):647-58 9759484 - Annu Rev Biochem. 1998;67:99-134 22852836 - Nucleic Acid Ther. 2012 Oct;22(5):344-59 17699775 - Cancer Res. 2007 Aug 15;67(16):7713-22 19748357 - Mol Cell. 2009 Sep 11;35(5):610-25 23080337 - Nat Rev Drug Discov. 2012 Nov;11(11):860-72 23982190 - Mol Ther Nucleic Acids. 2013 Aug 27;2:e117 23649362 - Nat Struct Mol Biol. 2013 May;20(5):541-3 16204072 - Cancer Res. 2005 Oct 1;65(19):8984-92 12408823 - Mol Cell. 2002 Sep;10(3):549-61 24511174 - Adv Drug Deliv Rev. 2012 Dec 1;64(Suppl):353-365 18362929 - Mol Ther. 2008 Apr;16(4):734-40 20305636 - Nature. 2010 Apr 15;464(7291):1067-70 24336348 - Toxicol Sci. 2014 Mar;138(1):234-48 16284623 - Nat Cell Biol. 2005 Dec;7(12):1261-6 21969601 - Mol Cell Biol. 2011 Dec;31(23):4760-74 12022830 - J Am Chem Soc. 2002 May 29;124(21):5974-82 20404851 - Nat Immunol. 2010 May;11(5):373-84 22517885 - Sci Transl Med. 2012 Apr 18;4(130):130ra48 15520458 - Nucleic Acids Res. 2004 Nov 01;32(19):e149 20351690 - Nat Biotechnol. 2010 Apr;28(4):341-7 22009537 - Cancer Res. 2011 Dec 15;71(24):7608-16 15531877 - Nature. 2004 Nov 11;432(7014):235-40 15880588 - Hepatology. 2005 Jun;41(6):1349-56 20855538 - RNA. 2010 Nov;16(11):2043-50 21900086 - Circulation. 2011 Oct 4;124(14 ):1537-47 7685712 - FEBS Lett. 1993 Jun 28;325(1-2):123-7 15172979 - Cancer Res. 2004 Jun 1;64(11):3753-6 16464133 - PLoS Med. 2006 Apr;3(4):e96 14976261 - Science. 2004 Mar 5;303(5663):1529-31 19965718 - Science. 2010 Jan 8;327(5962):198-201 10642801 - Dev Biol. 1999 Dec 15;216(2):671-80 18345015 - Nat Struct Mol Biol. 2008 Apr;15(4):346-53 18712719 - Angew Chem Int Ed Engl. 2008;47(39):7482-4 20018759 - Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):264-9 10706289 - Nature. 2000 Feb 24;403(6772):901-6 18521080 - Oncogene. 2008 Sep 25;27(43):5651-61 23792630 - Nat Biotechnol. 2013 Jul;31(7):638-46 16122423 - Cell. 2005 Aug 26;122(4):553-63 16565705 - Nature. 2006 May 4;441(7089):111-4 16041363 - Nat Biotechnol. 2005 Aug;23(8):1002-7 9547284 - Nucleic Acids Res. 1998 May 1;26(9):2224-9 17379774 - Science. 2007 Apr 27;316(5824):575-9 20055705 - Annu Rev Pharmacol Toxicol. 2010;50:259-93 15284443 - Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 16483934 - Mol Cell. 2006 Feb 17;21(4):533-42 19383765 - RNA. 2009 Jun;15(6):1005-11 17384677 - Oncogene. 2007 Sep 6;26(41):6099-105 18158133 - Methods. 2008 Jan;44(1):55-60 22545703 - Nucleic Acid Ther. 2012 Jun;22(3):152-61 20085706 - Cell. 2010 Jan 8;140(1):111-22 18158304 - Nucleic Acids Res. 2008 Mar;36(4):1153-62 8252622 - Cell. 1993 Dec 3;75(5):855-62 22344686 - Sci Transl Med. 2012 Feb 15;4(121):121ra18 19763153 - Nat Rev Genet. 2009 Oct;10(10):704-14 20703300 - Nature. 2010 Aug 12;466(7308):835-40 9486653 - Nature. 1998 Feb 19;391(6669):806-11 21778430 - Circ Res. 2011 Sep 2;109(6):670-9 8252621 - Cell. 1993 Dec 3;75(5):843-54 19043405 - Nature. 2008 Dec 18;456(7224):980-4 22052914 - Circ Res. 2012 Jan 6;110(1):71-81 19837467 - Trends Pharmacol Sci. 2009 Nov;30(11):592-9 19167326 - Cell. 2009 Jan 23;136(2):215-33 12923253 - RNA. 2003 Sep;9(9):1034-48 15652477 - Cell. 2005 Jan 14;120(1):15-20 16459310 - Cell Metab. 2006 Feb;3(2):87-98 21625215 - Oncogene. 2011 Nov 24;30(47):4750-6 16024602 - Cancer Res. 2005 Jul 15;65(14):6029-33 19135890 - Cell. 2009 Jan 9;136(1):75-84 22722835 - Nature. 2012 Jun 28;486(7404):541-4 7541132 - Nucleic Acids Res. 1995 Jun 11;23(11):2019-24 17363372 - J Biol Chem. 2007 May 11;282(19):14328-36 18368051 - Nature. 2008 Apr 17;452(7189):896-9 17108989 - Nat Chem Biol. 2006 Dec;2(12):711-9 16306938 - Nature. 2006 Jan 5;439(7072):89-94 23109665 - J Cell Biol. 2012 Oct 29;199(3):407-12 20527935 - J Am Chem Soc. 2010 Jun 16;132(23):7976-81 19219043 - Nat Genet. 2009 Mar;41(3):365-70 14691535 - PLoS Biol. 2003 Dec;1(3):E60 22608085 - Cell. 2012 Jun 22;149(7):1635-46 17694064 - Nat Methods. 2007 Sep;4(9):721-6 18239128 - Science. 2008 Feb 1;319(5863):627-30
References_xml	– volume: 105 start-page: 3903 year: 2008 end-page: 3908 ident: CR142 article-title: Suppression of non-small cell lung tumor development by the let-7 microRNA family publication-title: Proc. Natl Acad. Sci. USA – volume: 64 start-page: S24 year: 2012 end-page: S36 ident: CR131 article-title: Nanoparticles in cancer therapy and diagnosis publication-title: Adv. Drug Deliv. Rev. – volume: 4 start-page: 121ra118 year: 2012 ident: CR151 article-title: MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways publication-title: Sci. Transl. Med. – volume: 43 start-page: 371 year: 2011 end-page: 378 ident: CR80 article-title: Silencing of microRNA families by seed-targeting tiny LNAs publication-title: Nature Genet. – volume: 8 start-page: 555 year: 2012 end-page: 561 ident: CR73 article-title: Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing publication-title: Nature Chem. Biol. – volume: 136 start-page: 75 year: 2009 end-page: 84 ident: CR20 article-title: Posttranscriptional crossregulation between Drosha and DGCR8 publication-title: Cell – volume: 466 start-page: 835 year: 2010 end-page: 840 ident: CR34 article-title: Mammalian microRNAs predominantly act to decrease target mRNA levels publication-title: Nature doi: 10.1038/nature09267 – volume: 31 start-page: 577 year: 2013 end-page: 577 ident: CR137 article-title: First microRNA mimic enters clinic publication-title: Nature Biotech. – volume: 315 start-page: 1576 year: 2007 end-page: 1579 ident: CR141 article-title: Disrupting the pairing between and enhances oncogenic transformation publication-title: Science – volume: 2 start-page: E98 year: 2004 ident: CR59 article-title: Sequence-specific inhibition of small RNA function publication-title: PLoS Biol. – volume: 431 start-page: 350 year: 2004 end-page: 355 ident: CR4 article-title: The functions of animal microRNAs publication-title: Nature – volume: 10 start-page: 544 year: 2004 end-page: 550 ident: CR60 article-title: Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing publication-title: RNA – volume: 7 start-page: 771 year: 2008 end-page: 782 ident: CR95 article-title: Nanoparticle therapeutics: an emerging treatment modality for cancer publication-title: Nature Rev. Drug Discov. – volume: 439 start-page: 89 year: 2006 end-page: 94 ident: CR92 article-title: An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection publication-title: Nature – volume: 41 start-page: 365 year: 2009 end-page: 370 ident: CR24 article-title: A mutation in human cancer impairs microRNA processing and DICER1 function publication-title: Nature Genet. – volume: 20 start-page: 1885 year: 2006 end-page: 1898 ident: CR37 article-title: mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes publication-title: Genes Dev. – volume: 11 start-page: 860 year: 2012 end-page: 872 ident: CR10 article-title: MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles publication-title: Nature Rev. Drug Discov. – volume: 5 start-page: 381 year: 2009 end-page: 391 ident: CR62 article-title: Antisense oligonucleotide pharmacokinetics and metabolism publication-title: Expert Opin. Drug Metab. Toxicol. – volume: 436 start-page: 740 year: 2005 end-page: 744 ident: CR23 article-title: TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing publication-title: Nature – volume: 35 start-page: 610 year: 2009 end-page: 625 ident: CR107 article-title: miR-24 inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to “seedless” 3′UTR microRNA recognition elements publication-title: Mol. Cell – volume: 11 start-page: 373 year: 2010 end-page: 384 ident: CR111 article-title: The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors publication-title: Nature Immunol. – volume: 474 start-page: 649 year: 2011 end-page: 653 ident: CR161 article-title: MicroRNAs 103 and 107 regulate insulin sensitivity publication-title: Nature – volume: 32 start-page: 276 year: 2008 end-page: 284 ident: CR171 article-title: Lin28 mediates the terminal uridylation of let-7 precursor microRNA publication-title: Mol. Cell – volume: 34 start-page: 2294 year: 2006 end-page: 2304 ident: CR72 article-title: Improved targeting of miRNA with antisense oligonucleotides publication-title: Nucleic Acids Res. – volume: 303 start-page: 1526 year: 2004 end-page: 1529 ident: CR115 article-title: Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8 publication-title: Science – volume: 116 start-page: 281 year: 2004 end-page: 297 ident: CR3 article-title: MicroRNAs: genomics, biogenesis, mechanism, and function publication-title: Cell – volume: 4 start-page: e210 year: 2006 ident: CR38 article-title: Translation repression in human cells by microRNA-induced gene silencing requires RCK/p54 publication-title: PLoS Biol. – volume: 216 start-page: 671 year: 1999 end-page: 680 ident: CR30 article-title: The lin-4 regulatory RNA controls developmental timing in by blocking LIN-14 protein synthesis after the initiation of translation publication-title: Dev. Biol. – volume: 108 start-page: 15816 year: 2011 end-page: 15821 ident: CR85 article-title: Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer publication-title: Proc. Natl Acad. Sci. USA – volume: 23 start-page: 1002 year: 2005 end-page: 1007 ident: CR86 article-title: Potent and persistent anti-HBV activity of chemically modified siRNAs publication-title: Nature Biotech. – volume: 4 start-page: 130ra148 year: 2012 ident: CR106 article-title: Targeted delivery of PLK1-siRNA by ScFv suppresses Her2 breast cancer growth and metastasis publication-title: Sci. Transl. Med. – volume: 75 start-page: 843 year: 1993 end-page: 854 ident: CR27 article-title: The heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 publication-title: Cell – volume: 32 start-page: e149 year: 2004 ident: CR96 article-title: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle publication-title: Nucleic Acids Res. – volume: 101 start-page: 11755 year: 2004 end-page: 11760 ident: CR7 article-title: MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias publication-title: Proc. Natl Acad. Sci. USA – volume: 432 start-page: 173 year: 2004 end-page: 178 ident: CR65 article-title: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs publication-title: Nature – volume: 75 start-page: 855 year: 1993 end-page: 862 ident: CR28 article-title: Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in publication-title: Cell – volume: 11 start-page: 597 year: 2010 end-page: 610 ident: CR19 article-title: The widespread regulation of microRNA biogenesis, function and decay publication-title: Nature Rev. Genet. – volume: 67 start-page: 7713 year: 2007 end-page: 7722 ident: CR46 article-title: The let-7 microRNA represses cell proliferation pathways in human cells publication-title: Cancer Res. – volume: 46 start-page: 84 year: 2007 end-page: 94 ident: CR105 article-title: Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery publication-title: Hepatology – volume: 441 start-page: 111 year: 2006 end-page: 114 ident: CR88 article-title: RNAi-mediated gene silencing in non-human primates publication-title: Nature – volume: 30 start-page: 4750 year: 2011 end-page: 4756 ident: CR164 article-title: microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer publication-title: Oncogene – volume: 452 start-page: 896 year: 2008 end-page: 899 ident: CR17 article-title: LNA-mediated microRNA silencing in non-human primates publication-title: Nature – volume: 11 start-page: 263 year: 2005 end-page: 270 ident: CR117 article-title: Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 publication-title: Nature Med. – volume: 16 start-page: 734 year: 2008 end-page: 740 ident: CR83 article-title: Efficient delivery of siRNA to the liver by conjugation of alpha-tocopherol publication-title: Mol. Ther. – volume: 9 start-page: 775 year: 2010 end-page: 789 ident: CR126 article-title: Targeting microRNAs in cancer: rationale, strategies and challenges publication-title: Nature Rev. Drug Discov. – volume: 12 start-page: 247 year: 2010 end-page: 256 ident: CR43 article-title: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis publication-title: Nature Cell Biol. – volume: 104 start-page: 5715 year: 2007 end-page: 5721 ident: CR97 article-title: Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA publication-title: Proc. Natl Acad. Sci. USA – volume: 147 start-page: 344 year: 2011 end-page: 357 ident: CR49 article-title: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs publication-title: Cell – volume: 31 start-page: 638 year: 2013 end-page: 646 ident: CR133 article-title: Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape publication-title: Nature Biotech. – volume: 120 start-page: 635 year: 2005 end-page: 647 ident: CR140 article-title: RAS is regulated by the let-7 microRNA family publication-title: Cell – volume: 26 start-page: 561 year: 2008 end-page: 569 ident: CR89 article-title: A combinatorial library of lipid-like materials for delivery of RNAi therapeutics publication-title: Nature Biotech. – volume: 7 start-page: 759 year: 2008 end-page: 764 ident: CR143 article-title: The let-7 microRNA reduces tumor growth in mouse models of lung cancer publication-title: Cell Cycle – volume: 6 start-page: e20391 year: 2011 ident: CR168 article-title: Glycogen synthase kinase 3 beta (GSK3β) phosphorylates the RNAase III enzyme Drosha at S300 and S302 publication-title: PLoS ONE – volume: 27 start-page: 925 year: 2009 end-page: 932 ident: CR84 article-title: delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses publication-title: Nature Biotech. – volume: 1 start-page: E60 year: 2003 ident: CR40 article-title: Identification of microRNA targets publication-title: PLoS Biol. – volume: 413 start-page: 429 year: 2008 end-page: 436 ident: CR170 article-title: Phosphorylation of Argonaute 2 at serine-387 facilitates its localization to processing bodies publication-title: Biochem. J. – volume: 110 start-page: 187 year: 2013 end-page: 192 ident: CR156 article-title: Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family publication-title: Proc. Natl Acad. Sci. USA – volume: 65 start-page: 8984 year: 2005 end-page: 8992 ident: CR98 article-title: Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma publication-title: Cancer Res. – volume: 131 start-page: 1109 year: 2007 end-page: 1123 ident: CR144 article-title: let-7 regulates self renewal and tumorigenicity of breast cancer cells publication-title: Cell – volume: 10 start-page: 704 year: 2009 end-page: 714 ident: CR146 article-title: Causes and consequences of microRNA dysregulation in cancer publication-title: Nature Rev. Genet. – volume: 71 start-page: 7608 year: 2011 end-page: 7616 ident: CR160 article-title: miR-221 silencing blocks hepatocellular carcinoma and promotes survival publication-title: Cancer Res. – volume: 282 start-page: 14328 year: 2007 end-page: 14336 ident: CR148 article-title: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 ( ) publication-title: J. Biol. Chem. – volume: 5 start-page: e203 year: 2007 ident: CR108 article-title: Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development publication-title: PLoS Biol. – volume: 309 start-page: 1573 year: 2005 end-page: 1576 ident: CR29 article-title: Inhibition of translational initiation by Let-7 microRNA in human cells publication-title: Science – volume: 320 start-page: 1077 year: 2008 end-page: 1081 ident: CR6 article-title: Endogenous siRNAs derived from transposons and mRNAs in somatic cells publication-title: Science – volume: 199 start-page: 407 year: 2012 end-page: 412 ident: CR135 article-title: Discovering the first microRNA-targeted drug publication-title: J. Cell Biol. – volume: 20 start-page: 541 year: 2013 end-page: 543 ident: CR165 article-title: From pseudo-ceRNAs to circ-ceRNAs: a tale of cross-talk and competition publication-title: Nature Struct. Mol. Biol. – volume: 172 start-page: 6545 year: 2004 end-page: 6549 ident: CR112 article-title: Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3 publication-title: J. Immunol. – volume: 456 start-page: 980 year: 2008 end-page: 984 ident: CR67 article-title: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts publication-title: Nature – volume: 64 start-page: S353 year: 2012 end-page: S365 ident: CR132 article-title: Delivery of molecular and cellular medicine to solid tumors publication-title: Adv. Drug. Deliv. Rev. – volume: 432 start-page: 235 year: 2004 end-page: 240 ident: CR22 article-title: The microprocessor complex mediates the genesis of microRNAs publication-title: Nature – volume: 21 start-page: 201 year: 2011 end-page: 214 ident: CR118 article-title: Immunostimulatory potential of silencing RNAs can be mediated by a non-uridine-rich Toll-like receptor 7 motif publication-title: Nucleic Acid. Ther. – volume: 25 start-page: 1149 year: 2007 end-page: 1157 ident: CR82 article-title: Mechanisms and optimization of delivery of lipophilic siRNAs publication-title: Nature Biotech. – volume: 147 start-page: 358 year: 2011 end-page: 369 ident: CR50 article-title: A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA publication-title: Cell – volume: 64 start-page: S206 year: 2012 end-page: S212 ident: CR130 article-title: Nanoparticle and targeted systems for cancer therapy publication-title: Adv. Drug Deliv. Rev. – volume: 50 start-page: 259 year: 2010 end-page: 293 ident: CR119 article-title: RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform publication-title: Annu. Rev. Pharmacol. Toxicol. – volume: 4 start-page: 143 year: 2012 end-page: 159 ident: CR136 article-title: MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review publication-title: EMBO Mol. Med. – volume: 10 start-page: 111 year: 2010 end-page: 122 ident: CR11 article-title: Physiological and pathological roles for microRNAs in the immune system publication-title: Nature Rev. Immunol. – volume: 139 start-page: 112 year: 2009 end-page: 122 ident: CR25 article-title: Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling publication-title: Cell – volume: 120 start-page: 13252 year: 1998 end-page: 13253 ident: CR78 article-title: LNA (locked nucleic acid): an RNA mimic forming exceedingly stable LNA:LNA duplexes publication-title: J. Am. Chem. Soc. – volume: 7 start-page: 389 year: 2012 end-page: 393 ident: CR102 article-title: Molecularly self-assembled nucleic acid nanoparticles for targeted siRNA delivery publication-title: Nature Nanotech. – volume: 124 start-page: 1537 year: 2011 end-page: 1547 ident: CR153 article-title: Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure publication-title: Circulation – volume: 140 start-page: 111 year: 2010 end-page: 122 ident: CR162 article-title: Transcriptional control of gene expression by microRNAs publication-title: Cell – volume: 452 start-page: 591 year: 2008 end-page: 597 ident: CR113 article-title: Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 publication-title: Nature – volume: 65 start-page: 6029 year: 2005 end-page: 6033 ident: CR76 article-title: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells publication-title: Cancer Res. – volume: 1 start-page: e13 year: 2005 ident: CR41 article-title: microRNA target predictions across seven species and comparison to mammalian targets publication-title: PLoS Comput. Biol. – volume: 7 start-page: 1261 year: 2005 end-page: 1266 ident: CR35 article-title: A role for the P-body component GW182 in microRNA function publication-title: Nature Cell Biol. – volume: 30 start-page: 823 year: 2011 end-page: 834 ident: CR44 article-title: Small RNA-mediated regulation of iPS cell generation publication-title: EMBO J. – volume: 411 start-page: 494 year: 2001 end-page: 498 ident: CR2 article-title: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells publication-title: Nature – volume: 31 start-page: 4973 year: 2003 end-page: 4980 ident: CR54 article-title: Developmental defects by antisense-mediated inactivation of micro-RNAs 2 and 13 in and the identification of putative target genes publication-title: Nucleic Acids Res. – volume: 35 start-page: 687 year: 2007 end-page: 700 ident: CR123 article-title: Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals publication-title: Nucleic Acids Res. – volume: 44 start-page: 55 year: 2008 end-page: 60 ident: CR12 article-title: Inhibition of microRNA with antisense oligonucleotides publication-title: Methods – volume: 4 start-page: 721 year: 2007 end-page: 726 ident: CR47 article-title: MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells publication-title: Nature Methods – volume: 23 start-page: 709 year: 2005 end-page: 717 ident: CR103 article-title: Antibody mediated delivery of small interfering RNAs via cell-surface receptors publication-title: Nature Biotech. – volume: 486 start-page: 541 year: 2012 end-page: 544 ident: CR166 article-title: Autoregulation of microRNA biogenesis by let-7 and Argonaute publication-title: Nature – volume: 47 start-page: 7482 year: 2008 end-page: 7484 ident: CR52 article-title: Small-molecule inhibitors of microRNA miR-21 function publication-title: Angew. Chem. Int. Ed. Engl. – volume: 27 start-page: 5651 year: 2008 end-page: 5661 ident: CR157 article-title: miR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma publication-title: Oncogene – volume: 18 start-page: 1357 year: 2010 end-page: 1364 ident: CR90 article-title: Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms publication-title: Mol. Ther. – volume: 319 start-page: 627 year: 2008 end-page: 630 ident: CR91 article-title: Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target publication-title: Science – volume: 316 start-page: 575 year: 2007 end-page: 579 ident: CR152 article-title: Control of stress-dependent cardiac growth and gene expression by a microRNA publication-title: Science – volume: 309 start-page: 1577 year: 2005 end-page: 1581 ident: CR134 article-title: Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA publication-title: Science – volume: 101 start-page: 2999 year: 2004 end-page: 3004 ident: CR8 article-title: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers publication-title: Proc. Natl Acad. Sci. USA – volume: 22 start-page: 344 year: 2012 end-page: 359 ident: CR124 article-title: Chemical modification study of antisense gapmers publication-title: Nucleic Acid. Ther. – volume: 303 start-page: 1529 year: 2004 end-page: 1531 ident: CR114 article-title: Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA publication-title: Science – volume: 1998 start-page: 455 year: 1998 end-page: 456 ident: CR75 article-title: LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition publication-title: Chem. Comm. – volume: 283 start-page: 1026 year: 2008 end-page: 1033 ident: CR150 article-title: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells publication-title: J. Biol. Chem. – volume: 2 start-page: 711 year: 2006 end-page: 719 ident: CR14 article-title: RNAi therapeutics: a potential new class of pharmaceutical drugs publication-title: Nature Chem. Biol. – volume: 103 start-page: 2257 year: 2006 end-page: 2261 ident: CR145 article-title: A microRNA expression signature of human solid tumors defines cancer gene targets publication-title: Proc. Natl Acad. Sci. USA – volume: 1489 start-page: 117 year: 1999 end-page: 130 ident: CR69 article-title: 2′-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation publication-title: Biochim. Biophys. Acta – volume: 36 start-page: 831 year: 1993 end-page: 841 ident: CR71 article-title: Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets publication-title: J. Med. Chem. – volume: 16 start-page: 2043 year: 2010 end-page: 2050 ident: CR48 article-title: MicroRNA sponges: progress and possibilities publication-title: RNA – volume: 357 start-page: 2677 year: 2007 end-page: 2686 ident: CR109 article-title: Local dystrophin restoration with antisense oligonucleotide PRO051 publication-title: N. Engl. J. Med. – volume: 403 start-page: 901 year: 2000 end-page: 906 ident: CR138 article-title: The 21-nucleotide let-7 RNA regulates developmental timing in publication-title: Nature – volume: 104 start-page: 9667 year: 2007 end-page: 9672 ident: CR32 article-title: Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR publication-title: Proc. Natl Acad. Sci. USA – volume: 122 start-page: 553 year: 2005 end-page: 563 ident: CR33 article-title: Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation publication-title: Cell – volume: 147 start-page: 382 year: 2011 end-page: 395 ident: CR51 article-title: identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma publication-title: Cell – volume: 39 start-page: e38 year: 2011 ident: CR101 article-title: Silencing microRNA by interfering nanoparticles in mice publication-title: Nucleic Acids Res. – volume: 36 start-page: 1153 year: 2008 end-page: 1162 ident: CR79 article-title: Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver publication-title: Nucleic Acids Res. – volume: 15 start-page: 1005 year: 2009 end-page: 1011 ident: CR21 article-title: Post-transcriptional control of DGCR8 expression by the microprocessor publication-title: RNA – volume: 15 start-page: 5073 year: 2009 end-page: 5081 ident: CR158 article-title: MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality publication-title: Clin. Cancer Res. – volume: 107 start-page: 264 year: 2010 end-page: 269 ident: CR159 article-title: miR-221 overexpression contributes to liver tumorigenesis publication-title: Proc. Natl Acad. Sci. USA – volume: 64 start-page: 3753 year: 2004 end-page: 3756 ident: CR139 article-title: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival publication-title: Cancer Res. – volume: 23 start-page: 2019 year: 1995 end-page: 2024 ident: CR57 article-title: Characterization of fully 2′-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity publication-title: Nucleic Acids Res. – volume: 22 start-page: 152 year: 2012 end-page: 161 ident: CR122 article-title: A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys publication-title: Nucleic Acid Ther. – volume: 26 start-page: 6099 year: 2007 end-page: 6105 ident: CR127 article-title: Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92 publication-title: Oncogene – volume: 21 start-page: 533 year: 2006 end-page: 542 ident: CR31 article-title: Short RNAs repress translation after initiation in mammalian cells publication-title: Mol. Cell – volume: 136 start-page: 215 year: 2009 end-page: 233 ident: CR39 article-title: MicroRNAs: target recognition and regulatory functions publication-title: Cell – volume: 132 start-page: 7976 year: 2010 end-page: 7981 ident: CR53 article-title: Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma publication-title: J. Am. Chem. Soc. – volume: 27 start-page: 2128 year: 2008 end-page: 2136 ident: CR149 article-title: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer publication-title: Oncogene – volume: 110 start-page: 71 year: 2012 end-page: 81 ident: CR155 article-title: Inhibition of miR-15 protects against cardiac ischemic injury publication-title: Circ. Res. – volume: 67 start-page: 99 year: 1998 end-page: 134 ident: CR56 article-title: Modified oligonucleotides: synthesis and strategy for users publication-title: Annu. Rev. Biochem. – volume: 138 start-page: 234 year: 2013 end-page: 248 ident: CR125 article-title: Comparison of hepatic transcription profiles of locked ribonucleic acid (LNA) antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice publication-title: Toxicol. Sci. – volume: 26 start-page: 2224 year: 1998 end-page: 2229 ident: CR58 article-title: Advantages of 2′- -methyl oligoribonucleotide probes for detecting RNA targets publication-title: Nucleic Acids Res. – volume: 135 start-page: 3 year: 2008 end-page: 9 ident: CR5 article-title: Biogenesis and germline functions of piRNAs publication-title: Development – volume: 325 start-page: 123 year: 1993 end-page: 127 ident: CR55 article-title: Antisense oligonucleotides made of 2′- -alkylRNA: their properties and applications in RNA biochemistry publication-title: FEBS Lett. – volume: 7 start-page: 503 year: 1997 end-page: 510 ident: CR120 article-title: Inhibition of coagulation by a phosphorothioate oligonucleotide publication-title: Antisense Nucleic Acid Drug Dev. – volume: 2 start-page: 237 year: 2007 end-page: 241 ident: CR100 article-title: Design and creation of new nanomaterials for therapeutic RNAi publication-title: ACS Chem. Biol. – volume: 15 start-page: 346 year: 2008 end-page: 353 ident: CR36 article-title: GW182 interaction with Argonaute is essential for miRNA-mediated translational repression and mRNA decay publication-title: Nature Struct. Mol. Biol. – volume: 3 start-page: e96 year: 2006 ident: CR93 article-title: A single siRNA suppresses fatal encephalitis induced by two different flaviviruses publication-title: PLoS Med. – volume: 27 start-page: 1788 year: 2010 end-page: 1799 ident: CR61 article-title: A direct comparison of anti-microRNA oligonucleotide potency publication-title: Pharm. Res. – volume: 41 start-page: 1349 year: 2005 end-page: 1356 ident: CR87 article-title: Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication publication-title: Hepatology – volume: 18 start-page: 1111 year: 2011 end-page: 1120 ident: CR13 article-title: Chemical modification and design of anti-miRNA oligonucleotides publication-title: Gene Ther. – volume: 120 start-page: 15 year: 2005 end-page: 20 ident: CR26 article-title: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets publication-title: Cell – volume: 149 start-page: 1635 year: 2012 end-page: 1646 ident: CR167 article-title: Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons publication-title: Cell – volume: 327 start-page: 198 year: 2010 end-page: 201 ident: CR15 article-title: Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection publication-title: Science – volume: 391 start-page: 806 year: 1998 end-page: 811 ident: CR1 article-title: Potent and specific genetic interference by double-stranded RNA in publication-title: Nature doi: 10.1038/35888 – volume: 10 start-page: 549 year: 2002 end-page: 561 ident: CR63 article-title: RNAi in human cells: basic structural and functional features of small interfering RNA publication-title: Mol. Cell – volume: 8 start-page: 69 year: 2007 ident: CR42 article-title: Inference of miRNA targets using evolutionary conservation and pathway analysis publication-title: BMC Bioinformatics – volume: 464 start-page: 1067 year: 2010 end-page: 1070 ident: CR99 article-title: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles publication-title: Nature – volume: 109 start-page: 670 year: 2011 end-page: 679 ident: CR154 article-title: miR-15 family regulates postnatal mitotic arrest of cardiomyocytes publication-title: Circ. Res. – volume: 45 start-page: 1122 year: 2012 end-page: 1131 ident: CR18 article-title: Molecular mechanisms of RNA-triggered gene silencing machineries publication-title: Accounts Chem. Res. – volume: 28 start-page: 341 year: 2010 end-page: 347 ident: CR68 article-title: Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model publication-title: Nature Biotech. – volume: 133 start-page: 647 year: 2007 end-page: 658 ident: CR147 article-title: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer publication-title: Gastroenterology – volume: 30 start-page: 592 year: 2009 end-page: 599 ident: CR94 article-title: Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer publication-title: Trends Pharmacol. Sci. – volume: 124 start-page: 5974 year: 2002 end-page: 5982 ident: CR74 article-title: Locked nucleic acid (LNA) recognition of RNA: NMR solution structures of LNA:RNA hybrids publication-title: J. Am. Chem. Soc. – volume: 372 start-page: 137 year: 2006 end-page: 141 ident: CR77 article-title: LNA-modified oligonucleotides mediate specific inhibition of microRNA function publication-title: Gene – volume: 132 start-page: 875 year: 2008 end-page: 886 ident: CR128 article-title: Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters publication-title: Cell – volume: 23 start-page: 457 year: 2005 end-page: 462 ident: CR116 article-title: Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA publication-title: Nature Biotech. – volume: 12 start-page: 478 year: 2010 end-page: 486 ident: CR110 article-title: PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy publication-title: Curr. Opin. Mol. Ther. – volume: 223 start-page: 102 year: 2011 end-page: 115 ident: CR9 article-title: miRNAs in human cancer publication-title: J. Pathol. – volume: 438 start-page: 685 year: 2005 end-page: 689 ident: CR16 article-title: Silencing of microRNAs with 'antagomirs' publication-title: Nature – volume: 68 start-page: 8164 year: 2008 end-page: 8172 ident: CR45 article-title: MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells publication-title: Cancer Res. – volume: 9 start-page: 1034 year: 2003 end-page: 1048 ident: CR64 article-title: siRNA function in RNAi: a chemical modification analysis publication-title: RNA – volume: 150 start-page: 895 year: 2012 end-page: 908 ident: CR66 article-title: Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression publication-title: Cell – volume: 14 start-page: 849 year: 2013 end-page: 857 ident: CR129 article-title: MicroRNAs of the miR-17 approximately 92 family are critical regulators of TFH differentiation publication-title: Nature Immunol. – volume: 2 start-page: e117 year: 2013 ident: CR81 article-title: Improved performance of anti-miRNA oligonucleotides using a novel non-nucleotide modifier publication-title: Mol. Ther. Nucleic Acids – volume: 140 start-page: 652 year: 2010 end-page: 665 ident: CR163 article-title: miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts publication-title: Cell – volume: 31 start-page: 4760 year: 2011 end-page: 4774 ident: CR169 article-title: Hypoxia potentiates microRNA-mediated gene silencing through posttranslational modification of Argonaute2 publication-title: Mol. Cell. Biol. – volume: 3 start-page: 87 year: 2006 end-page: 98 ident: CR70 article-title: miR-122 regulation of lipid metabolism revealed by antisense targeting publication-title: Cell. Metab. – volume: 134 start-page: 577 year: 2008 end-page: 586 ident: CR104 article-title: T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice publication-title: Cell – volume: 4 start-page: 201 year: 1994 end-page: 206 ident: CR121 article-title: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey publication-title: Antisense Res. Dev. – volume: 2 start-page: 237 year: 2007 ident: BFnrd4359_CR100 publication-title: ACS Chem. Biol. doi: 10.1021/cb7000582 – volume: 439 start-page: 89 year: 2006 ident: BFnrd4359_CR92 publication-title: Nature doi: 10.1038/nature04263 – volume: 3 start-page: 87 year: 2006 ident: BFnrd4359_CR70 publication-title: Cell. Metab. doi: 10.1016/j.cmet.2006.01.005 – volume: 44 start-page: 55 year: 2008 ident: BFnrd4359_CR12 publication-title: Methods doi: 10.1016/j.ymeth.2007.11.001 – volume: 372 start-page: 137 year: 2006 ident: BFnrd4359_CR77 publication-title: Gene doi: 10.1016/j.gene.2005.12.031 – volume: 441 start-page: 111 year: 2006 ident: BFnrd4359_CR88 publication-title: Nature doi: 10.1038/nature04688 – volume: 7 start-page: 759 year: 2008 ident: BFnrd4359_CR143 publication-title: Cell Cycle doi: 10.4161/cc.7.6.5834 – volume: 436 start-page: 740 year: 2005 ident: BFnrd4359_CR23 publication-title: Nature doi: 10.1038/nature03868 – volume: 110 start-page: 71 year: 2012 ident: BFnrd4359_CR155 publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.111.244442 – volume: 223 start-page: 102 year: 2011 ident: BFnrd4359_CR9 publication-title: J. Pathol. doi: 10.1002/path.2806 – volume: 68 start-page: 8164 year: 2008 ident: BFnrd4359_CR45 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-1305 – volume: 132 start-page: 7976 year: 2010 ident: BFnrd4359_CR53 publication-title: J. Am. Chem. Soc. doi: 10.1021/ja910275u – volume: 7 start-page: 771 year: 2008 ident: BFnrd4359_CR95 publication-title: Nature Rev. Drug Discov. doi: 10.1038/nrd2614 – volume: 147 start-page: 344 year: 2011 ident: BFnrd4359_CR49 publication-title: Cell doi: 10.1016/j.cell.2011.09.029 – volume: 67 start-page: 99 year: 1998 ident: BFnrd4359_CR56 publication-title: Annu. Rev. Biochem. doi: 10.1146/annurev.biochem.67.1.99 – volume: 27 start-page: 2128 year: 2008 ident: BFnrd4359_CR149 publication-title: Oncogene doi: 10.1038/sj.onc.1210856 – volume: 23 start-page: 709 year: 2005 ident: BFnrd4359_CR103 publication-title: Nature Biotech. doi: 10.1038/nbt1101 – volume: 12 start-page: 247 year: 2010 ident: BFnrd4359_CR43 publication-title: Nature Cell Biol. doi: 10.1038/ncb2024 – volume: 20 start-page: 1885 year: 2006 ident: BFnrd4359_CR37 publication-title: Genes Dev. doi: 10.1101/gad.1424106 – volume: 105 start-page: 3903 year: 2008 ident: BFnrd4359_CR142 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0712321105 – volume: 6 start-page: e20391 year: 2011 ident: BFnrd4359_CR168 publication-title: PLoS ONE doi: 10.1371/journal.pone.0020391 – volume: 413 start-page: 429 year: 2008 ident: BFnrd4359_CR170 publication-title: Biochem. J. doi: 10.1042/BJ20080599 – volume: 432 start-page: 235 year: 2004 ident: BFnrd4359_CR22 publication-title: Nature doi: 10.1038/nature03120 – volume: 36 start-page: 831 year: 1993 ident: BFnrd4359_CR71 publication-title: J. Med. Chem. doi: 10.1021/jm00059a007 – volume: 319 start-page: 627 year: 2008 ident: BFnrd4359_CR91 publication-title: Science doi: 10.1126/science.1149859 – volume: 431 start-page: 350 year: 2004 ident: BFnrd4359_CR4 publication-title: Nature doi: 10.1038/nature02871 – volume: 109 start-page: 670 year: 2011 ident: BFnrd4359_CR154 publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.111.248880 – volume: 8 start-page: 555 year: 2012 ident: BFnrd4359_CR73 publication-title: Nature Chem. Biol. doi: 10.1038/nchembio.939 – volume: 30 start-page: 592 year: 2009 ident: BFnrd4359_CR94 publication-title: Trends Pharmacol. Sci. doi: 10.1016/j.tips.2009.08.004 – volume: 325 start-page: 123 year: 1993 ident: BFnrd4359_CR55 publication-title: FEBS Lett. doi: 10.1016/0014-5793(93)81427-2 – volume: 120 start-page: 635 year: 2005 ident: BFnrd4359_CR140 publication-title: Cell doi: 10.1016/j.cell.2005.01.014 – volume: 1998 start-page: 455 year: 1998 ident: BFnrd4359_CR75 publication-title: Chem. Comm. doi: 10.1039/a708608c – volume: 27 start-page: 925 year: 2009 ident: BFnrd4359_CR84 publication-title: Nature Biotech. doi: 10.1038/nbt.1564 – volume: 21 start-page: 201 year: 2011 ident: BFnrd4359_CR118 publication-title: Nucleic Acid. Ther. doi: 10.1089/nat.2011.0298 – volume: 64 start-page: S206 year: 2012 ident: BFnrd4359_CR130 publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2012.09.033 – volume: 108 start-page: 15816 year: 2011 ident: BFnrd4359_CR85 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1016152108 – volume: 75 start-page: 855 year: 1993 ident: BFnrd4359_CR28 publication-title: Cell doi: 10.1016/0092-8674(93)90530-4 – volume: 7 start-page: 389 year: 2012 ident: BFnrd4359_CR102 publication-title: Nature Nanotech. doi: 10.1038/nnano.2012.73 – volume: 27 start-page: 5651 year: 2008 ident: BFnrd4359_CR157 publication-title: Oncogene doi: 10.1038/onc.2008.178 – volume: 5 start-page: 381 year: 2009 ident: BFnrd4359_CR62 publication-title: Expert Opin. Drug Metab. Toxicol. doi: 10.1517/17425250902877680 – volume: 9 start-page: 775 year: 2010 ident: BFnrd4359_CR126 publication-title: Nature Rev. Drug Discov. doi: 10.1038/nrd3179 – volume: 4 start-page: 130ra148 year: 2012 ident: BFnrd4359_CR106 publication-title: Sci. Transl. Med. – volume: 120 start-page: 13252 year: 1998 ident: BFnrd4359_CR78 publication-title: J. Am. Chem. Soc. doi: 10.1021/ja9822862 – volume: 11 start-page: 597 year: 2010 ident: BFnrd4359_CR19 publication-title: Nature Rev. Genet. doi: 10.1038/nrg2843 – volume: 46 start-page: 84 year: 2007 ident: BFnrd4359_CR105 publication-title: Hepatology doi: 10.1002/hep.21663 – volume: 131 start-page: 1109 year: 2007 ident: BFnrd4359_CR144 publication-title: Cell doi: 10.1016/j.cell.2007.10.054 – volume: 101 start-page: 11755 year: 2004 ident: BFnrd4359_CR7 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0404432101 – volume: 136 start-page: 75 year: 2009 ident: BFnrd4359_CR20 publication-title: Cell doi: 10.1016/j.cell.2008.10.053 – volume: 15 start-page: 1005 year: 2009 ident: BFnrd4359_CR21 publication-title: RNA doi: 10.1261/rna.1591709 – volume: 28 start-page: 341 year: 2010 ident: BFnrd4359_CR68 publication-title: Nature Biotech. doi: 10.1038/nbt.1618 – volume: 9 start-page: 1034 year: 2003 ident: BFnrd4359_CR64 publication-title: RNA doi: 10.1261/rna.5103703 – volume: 303 start-page: 1529 year: 2004 ident: BFnrd4359_CR114 publication-title: Science doi: 10.1126/science.1093616 – volume: 135 start-page: 3 year: 2008 ident: BFnrd4359_CR5 publication-title: Development doi: 10.1242/dev.006486 – volume: 35 start-page: 610 year: 2009 ident: BFnrd4359_CR107 publication-title: Mol. Cell doi: 10.1016/j.molcel.2009.08.020 – volume: 438 start-page: 685 year: 2005 ident: BFnrd4359_CR16 publication-title: Nature doi: 10.1038/nature04303 – volume: 45 start-page: 1122 year: 2012 ident: BFnrd4359_CR18 publication-title: Accounts Chem. Res. doi: 10.1021/ar200253u – volume: 10 start-page: 544 year: 2004 ident: BFnrd4359_CR60 publication-title: RNA doi: 10.1261/rna.5235104 – volume: 41 start-page: 365 year: 2009 ident: BFnrd4359_CR24 publication-title: Nature Genet. doi: 10.1038/ng.317 – volume: 11 start-page: 263 year: 2005 ident: BFnrd4359_CR117 publication-title: Nature Med. doi: 10.1038/nm1191 – volume: 71 start-page: 7608 year: 2011 ident: BFnrd4359_CR160 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-11-1144 – volume: 47 start-page: 7482 year: 2008 ident: BFnrd4359_CR52 publication-title: Angew. Chem. Int. Ed. Engl. doi: 10.1002/anie.200801555 – volume: 1 start-page: E60 year: 2003 ident: BFnrd4359_CR40 publication-title: PLoS Biol. doi: 10.1371/journal.pbio.0000060 – volume: 134 start-page: 577 year: 2008 ident: BFnrd4359_CR104 publication-title: Cell doi: 10.1016/j.cell.2008.06.034 – volume: 34 start-page: 2294 year: 2006 ident: BFnrd4359_CR72 publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkl183 – volume: 133 start-page: 647 year: 2007 ident: BFnrd4359_CR147 publication-title: Gastroenterology doi: 10.1053/j.gastro.2007.05.022 – volume: 65 start-page: 6029 year: 2005 ident: BFnrd4359_CR76 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-05-0137 – volume: 282 start-page: 14328 year: 2007 ident: BFnrd4359_CR148 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M611393200 – volume: 150 start-page: 895 year: 2012 ident: BFnrd4359_CR66 publication-title: Cell doi: 10.1016/j.cell.2012.08.002 – volume: 309 start-page: 1573 year: 2005 ident: BFnrd4359_CR29 publication-title: Science doi: 10.1126/science.1115079 – volume: 403 start-page: 901 year: 2000 ident: BFnrd4359_CR138 publication-title: Nature doi: 10.1038/35002607 – volume: 27 start-page: 1788 year: 2010 ident: BFnrd4359_CR61 publication-title: Pharm. Res. doi: 10.1007/s11095-010-0156-0 – volume: 5 start-page: e203 year: 2007 ident: BFnrd4359_CR108 publication-title: PLoS Biol. doi: 10.1371/journal.pbio.0050203 – volume: 10 start-page: 704 year: 2009 ident: BFnrd4359_CR146 publication-title: Nature Rev. Genet. doi: 10.1038/nrg2634 – volume: 2 start-page: 711 year: 2006 ident: BFnrd4359_CR14 publication-title: Nature Chem. Biol. doi: 10.1038/nchembio839 – volume: 122 start-page: 553 year: 2005 ident: BFnrd4359_CR33 publication-title: Cell doi: 10.1016/j.cell.2005.07.031 – volume: 10 start-page: 111 year: 2010 ident: BFnrd4359_CR11 publication-title: Nature Rev. Immunol. doi: 10.1038/nri2708 – volume: 140 start-page: 652 year: 2010 ident: BFnrd4359_CR163 publication-title: Cell doi: 10.1016/j.cell.2010.01.007 – volume: 30 start-page: 823 year: 2011 ident: BFnrd4359_CR44 publication-title: EMBO J. doi: 10.1038/emboj.2011.2 – volume: 124 start-page: 1537 year: 2011 ident: BFnrd4359_CR153 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.111.030932 – volume: 7 start-page: 1261 year: 2005 ident: BFnrd4359_CR35 publication-title: Nature Cell Biol. doi: 10.1038/ncb1333 – volume: 64 start-page: S353 year: 2012 ident: BFnrd4359_CR132 publication-title: Adv. Drug. Deliv. Rev. doi: 10.1016/j.addr.2012.09.011 – volume: 4 start-page: 143 year: 2012 ident: BFnrd4359_CR136 publication-title: EMBO Mol. Med. doi: 10.1002/emmm.201100209 – volume: 25 start-page: 1149 year: 2007 ident: BFnrd4359_CR82 publication-title: Nature Biotech. doi: 10.1038/nbt1339 – volume: 474 start-page: 649 year: 2011 ident: BFnrd4359_CR161 publication-title: Nature doi: 10.1038/nature10112 – volume: 3 start-page: e96 year: 2006 ident: BFnrd4359_CR93 publication-title: PLoS Med. doi: 10.1371/journal.pmed.0030096 – volume: 116 start-page: 281 year: 2004 ident: BFnrd4359_CR3 publication-title: Cell doi: 10.1016/S0092-8674(04)00045-5 – volume: 21 start-page: 533 year: 2006 ident: BFnrd4359_CR31 publication-title: Mol. Cell doi: 10.1016/j.molcel.2006.01.031 – volume: 16 start-page: 2043 year: 2010 ident: BFnrd4359_CR48 publication-title: RNA doi: 10.1261/rna.2414110 – volume: 283 start-page: 1026 year: 2008 ident: BFnrd4359_CR150 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M707224200 – volume: 320 start-page: 1077 year: 2008 ident: BFnrd4359_CR6 publication-title: Science doi: 10.1126/science.1157396 – volume: 464 start-page: 1067 year: 2010 ident: BFnrd4359_CR99 publication-title: Nature doi: 10.1038/nature08956 – volume: 64 start-page: S24 year: 2012 ident: BFnrd4359_CR131 publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2012.09.006 – volume: 31 start-page: 4973 year: 2003 ident: BFnrd4359_CR54 publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkg707 – volume: 31 start-page: 577 year: 2013 ident: BFnrd4359_CR137 publication-title: Nature Biotech. doi: 10.1038/nbt0713-577 – volume: 32 start-page: e149 year: 2004 ident: BFnrd4359_CR96 publication-title: Nucleic Acids Res. doi: 10.1093/nar/gnh140 – volume: 67 start-page: 7713 year: 2007 ident: BFnrd4359_CR46 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-07-1083 – volume: 1489 start-page: 117 year: 1999 ident: BFnrd4359_CR69 publication-title: Biochim. Biophys. Acta doi: 10.1016/S0167-4781(99)00138-4 – volume: 309 start-page: 1577 year: 2005 ident: BFnrd4359_CR134 publication-title: Science doi: 10.1126/science.1113329 – volume: 391 start-page: 806 year: 1998 ident: BFnrd4359_CR1 publication-title: Nature doi: 10.1038/35888 – volume: 4 start-page: 121ra118 year: 2012 ident: BFnrd4359_CR151 publication-title: Sci. Transl. Med. – volume: 140 start-page: 111 year: 2010 ident: BFnrd4359_CR162 publication-title: Cell doi: 10.1016/j.cell.2009.12.023 – volume: 4 start-page: 721 year: 2007 ident: BFnrd4359_CR47 publication-title: Nature Methods doi: 10.1038/nmeth1079 – volume: 107 start-page: 264 year: 2010 ident: BFnrd4359_CR159 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0907904107 – volume: 15 start-page: 5073 year: 2009 ident: BFnrd4359_CR158 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-0092 – volume: 216 start-page: 671 year: 1999 ident: BFnrd4359_CR30 publication-title: Dev. Biol. doi: 10.1006/dbio.1999.9523 – volume: 147 start-page: 358 year: 2011 ident: BFnrd4359_CR50 publication-title: Cell doi: 10.1016/j.cell.2011.09.028 – volume: 104 start-page: 9667 year: 2007 ident: BFnrd4359_CR32 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0703820104 – volume: 4 start-page: e210 year: 2006 ident: BFnrd4359_CR38 publication-title: PLoS Biol. doi: 10.1371/journal.pbio.0040210 – volume: 147 start-page: 382 year: 2011 ident: BFnrd4359_CR51 publication-title: Cell doi: 10.1016/j.cell.2011.09.032 – volume: 452 start-page: 591 year: 2008 ident: BFnrd4359_CR113 publication-title: Nature doi: 10.1038/nature06765 – volume: 149 start-page: 1635 year: 2012 ident: BFnrd4359_CR167 publication-title: Cell doi: 10.1016/j.cell.2012.05.003 – volume: 139 start-page: 112 year: 2009 ident: BFnrd4359_CR25 publication-title: Cell doi: 10.1016/j.cell.2009.06.044 – volume: 26 start-page: 561 year: 2008 ident: BFnrd4359_CR89 publication-title: Nature Biotech. doi: 10.1038/nbt1402 – volume: 11 start-page: 373 year: 2010 ident: BFnrd4359_CR111 publication-title: Nature Immunol. doi: 10.1038/ni.1863 – volume: 456 start-page: 980 year: 2008 ident: BFnrd4359_CR67 publication-title: Nature doi: 10.1038/nature07511 – volume: 36 start-page: 1153 year: 2008 ident: BFnrd4359_CR79 publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkm1113 – volume: 16 start-page: 734 year: 2008 ident: BFnrd4359_CR83 publication-title: Mol. Ther. doi: 10.1038/mt.2008.14 – volume: 18 start-page: 1111 year: 2011 ident: BFnrd4359_CR13 publication-title: Gene Ther. doi: 10.1038/gt.2011.100 – volume: 101 start-page: 2999 year: 2004 ident: BFnrd4359_CR8 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0307323101 – volume: 411 start-page: 494 year: 2001 ident: BFnrd4359_CR2 publication-title: Nature doi: 10.1038/35078107 – volume: 14 start-page: 849 year: 2013 ident: BFnrd4359_CR129 publication-title: Nature Immunol. doi: 10.1038/ni.2648 – volume: 75 start-page: 843 year: 1993 ident: BFnrd4359_CR27 publication-title: Cell doi: 10.1016/0092-8674(93)90529-Y – volume: 124 start-page: 5974 year: 2002 ident: BFnrd4359_CR74 publication-title: J. Am. Chem. Soc. doi: 10.1021/ja012288d – volume: 172 start-page: 6545 year: 2004 ident: BFnrd4359_CR112 publication-title: J. Immunol. doi: 10.4049/jimmunol.172.11.6545 – volume: 31 start-page: 4760 year: 2011 ident: BFnrd4359_CR169 publication-title: Mol. Cell. Biol. doi: 10.1128/MCB.05776-11 – volume: 11 start-page: 860 year: 2012 ident: BFnrd4359_CR10 publication-title: Nature Rev. Drug Discov. doi: 10.1038/nrd3864 – volume: 138 start-page: 234 year: 2013 ident: BFnrd4359_CR125 publication-title: Toxicol. Sci. doi: 10.1093/toxsci/kft278 – volume: 315 start-page: 1576 year: 2007 ident: BFnrd4359_CR141 publication-title: Science doi: 10.1126/science.1137999 – volume: 8 start-page: 69 year: 2007 ident: BFnrd4359_CR42 publication-title: BMC Bioinformatics doi: 10.1186/1471-2105-8-69 – volume: 31 start-page: 638 year: 2013 ident: BFnrd4359_CR133 publication-title: Nature Biotech. doi: 10.1038/nbt.2612 – volume: 2 start-page: e117 year: 2013 ident: BFnrd4359_CR81 publication-title: Mol. Ther. Nucleic Acids doi: 10.1038/mtna.2013.46 – volume: 110 start-page: 187 year: 2013 ident: BFnrd4359_CR156 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1208863110 – volume: 26 start-page: 2224 year: 1998 ident: BFnrd4359_CR58 publication-title: Nucleic Acids Res. doi: 10.1093/nar/26.9.2224 – volume: 32 start-page: 276 year: 2008 ident: BFnrd4359_CR171 publication-title: Mol. Cell doi: 10.1016/j.molcel.2008.09.014 – volume: 327 start-page: 198 year: 2010 ident: BFnrd4359_CR15 publication-title: Science doi: 10.1126/science.1178178 – volume: 12 start-page: 478 year: 2010 ident: BFnrd4359_CR110 publication-title: Curr. Opin. Mol. Ther. – volume: 50 start-page: 259 year: 2010 ident: BFnrd4359_CR119 publication-title: Annu. Rev. Pharmacol. Toxicol. doi: 10.1146/annurev.pharmtox.010909.105654 – volume: 35 start-page: 687 year: 2007 ident: BFnrd4359_CR123 publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkl1071 – volume: 64 start-page: 3753 year: 2004 ident: BFnrd4359_CR139 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-04-0637 – volume: 1 start-page: e13 year: 2005 ident: BFnrd4359_CR41 publication-title: PLoS Comput. Biol. doi: 10.1371/journal.pcbi.0010013 – volume: 120 start-page: 15 year: 2005 ident: BFnrd4359_CR26 publication-title: Cell doi: 10.1016/j.cell.2004.12.035 – volume: 26 start-page: 6099 year: 2007 ident: BFnrd4359_CR127 publication-title: Oncogene doi: 10.1038/sj.onc.1210425 – volume: 316 start-page: 575 year: 2007 ident: BFnrd4359_CR152 publication-title: Science doi: 10.1126/science.1139089 – volume: 15 start-page: 346 year: 2008 ident: BFnrd4359_CR36 publication-title: Nature Struct. Mol. Biol. doi: 10.1038/nsmb.1405 – volume: 104 start-page: 5715 year: 2007 ident: BFnrd4359_CR97 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0701458104 – volume: 103 start-page: 2257 year: 2006 ident: BFnrd4359_CR145 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0510565103 – volume: 486 start-page: 541 year: 2012 ident: BFnrd4359_CR166 publication-title: Nature doi: 10.1038/nature11134 – volume: 2 start-page: E98 year: 2004 ident: BFnrd4359_CR59 publication-title: PLoS Biol. doi: 10.1371/journal.pbio.0020098 – volume: 23 start-page: 457 year: 2005 ident: BFnrd4359_CR116 publication-title: Nature Biotech. doi: 10.1038/nbt1081 – volume: 4 start-page: 201 year: 1994 ident: BFnrd4359_CR121 publication-title: Antisense Res. Dev. doi: 10.1089/ard.1994.4.201 – volume: 452 start-page: 896 year: 2008 ident: BFnrd4359_CR17 publication-title: Nature doi: 10.1038/nature06783 – volume: 466 start-page: 835 year: 2010 ident: BFnrd4359_CR34 publication-title: Nature doi: 10.1038/nature09267 – volume: 7 start-page: 503 year: 1997 ident: BFnrd4359_CR120 publication-title: Antisense Nucleic Acid Drug Dev. doi: 10.1089/oli.1.1997.7.503 – volume: 22 start-page: 152 year: 2012 ident: BFnrd4359_CR122 publication-title: Nucleic Acid Ther. doi: 10.1089/nat.2011.0332 – volume: 43 start-page: 371 year: 2011 ident: BFnrd4359_CR80 publication-title: Nature Genet. doi: 10.1038/ng.786 – volume: 132 start-page: 875 year: 2008 ident: BFnrd4359_CR128 publication-title: Cell doi: 10.1016/j.cell.2008.02.019 – volume: 23 start-page: 2019 year: 1995 ident: BFnrd4359_CR57 publication-title: Nucleic Acids Res. doi: 10.1093/nar/23.11.2019 – volume: 18 start-page: 1357 year: 2010 ident: BFnrd4359_CR90 publication-title: Mol. Ther. doi: 10.1038/mt.2010.85 – volume: 10 start-page: 549 year: 2002 ident: BFnrd4359_CR63 publication-title: Mol. Cell doi: 10.1016/S1097-2765(02)00652-4 – volume: 23 start-page: 1002 year: 2005 ident: BFnrd4359_CR86 publication-title: Nature Biotech. doi: 10.1038/nbt1122 – volume: 22 start-page: 344 year: 2012 ident: BFnrd4359_CR124 publication-title: Nucleic Acid. Ther. doi: 10.1089/nat.2012.0366 – volume: 30 start-page: 4750 year: 2011 ident: BFnrd4359_CR164 publication-title: Oncogene doi: 10.1038/onc.2011.193 – volume: 41 start-page: 1349 year: 2005 ident: BFnrd4359_CR87 publication-title: Hepatology doi: 10.1002/hep.20702 – volume: 136 start-page: 215 year: 2009 ident: BFnrd4359_CR39 publication-title: Cell doi: 10.1016/j.cell.2009.01.002 – volume: 65 start-page: 8984 year: 2005 ident: BFnrd4359_CR98 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-05-0565 – volume: 432 start-page: 173 year: 2004 ident: BFnrd4359_CR65 publication-title: Nature doi: 10.1038/nature03121 – volume: 39 start-page: e38 year: 2011 ident: BFnrd4359_CR101 publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkq1307 – volume: 199 start-page: 407 year: 2012 ident: BFnrd4359_CR135 publication-title: J. Cell Biol. doi: 10.1083/jcb.201208082 – volume: 357 start-page: 2677 year: 2007 ident: BFnrd4359_CR109 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa073108 – volume: 303 start-page: 1526 year: 2004 ident: BFnrd4359_CR115 publication-title: Science doi: 10.1126/science.1093620 – volume: 20 start-page: 541 year: 2013 ident: BFnrd4359_CR165 publication-title: Nature Struct. Mol. Biol. doi: 10.1038/nsmb.2580 – reference: 15024405 - PLoS Biol. 2004 Apr;2(4):E98 – reference: 9759484 - Annu Rev Biochem. 1998;67:99-134 – reference: 16690972 - Nucleic Acids Res. 2006 May 11;34(8):2294-304 – reference: 14691535 - PLoS Biol. 2003 Dec;1(3):E60 – reference: 9361909 - Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):503-10 – reference: 20424893 - Pharm Res. 2010 Sep;27(9):1788-99 – reference: 18308936 - Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3903-8 – reference: 19763153 - Nat Rev Genet. 2009 Oct;10(10):704-14 – reference: 11373684 - Nature. 2001 May 24;411(6836):494-8 – reference: 20351690 - Nat Biotechnol. 2010 Apr;28(4):341-7 – reference: 19837467 - Trends Pharmacol Sci. 2009 Nov;30(11):592-9 – reference: 15908939 - Nat Biotechnol. 2005 Jun;23(6):709-17 – reference: 23109665 - J Cell Biol. 2012 Oct 29;199(3):407-12 – reference: 9547284 - Nucleic Acids Res. 1998 May 1;26(9):2224-9 – reference: 17432823 - ACS Chem Biol. 2007 Apr 24;2(4):237-41 – reference: 20703300 - Nature. 2010 Aug 12;466(7308):835-40 – reference: 22000014 - Cell. 2011 Oct 14;147(2):358-69 – reference: 22000016 - Cell. 2011 Oct 14;147(2):382-95 – reference: 21285944 - EMBO J. 2011 Mar 2;30(5):823-34 – reference: 15153468 - J Immunol. 2004 Jun 1;172(11):6545-9 – reference: 23812097 - Nat Immunol. 2013 Aug;14(8):849-57 – reference: 18160687 - N Engl J Med. 2007 Dec 27;357(26):2677-86 – reference: 20055705 - Annu Rev Pharmacol Toxicol. 2010;50:259-93 – reference: 19167326 - Cell. 2009 Jan 23;136(2):215-33 – reference: 16103902 - PLoS Comput Biol. 2005 Jun;1(1):e13 – reference: 15652477 - Cell. 2005 Jan 14;120(1):15-20 – reference: 18476811 - Biochem J. 2008 Aug 1;413(3):429-36 – reference: 18368052 - Nature. 2008 Apr 3;452(7187):591-7 – reference: 22504300 - Nat Chem Biol. 2012 Apr 15;8(6):555-61 – reference: 18083101 - Cell. 2007 Dec 14;131(6):1109-23 – reference: 16459310 - Cell Metab. 2006 Feb;3(2):87-98 – reference: 16815998 - Genes Dev. 2006 Jul 15;20(14):1885-98 – reference: 21654750 - Nature. 2011 Jun 08;474(7353):649-53 – reference: 15284443 - Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 – reference: 18032451 - Development. 2008 Jan;135(1):3-9 – reference: 21778430 - Circ Res. 2011 Sep 2;109(6):670-9 – reference: 17322030 - Science. 2007 Mar 16;315(5818):1576-9 – reference: 23839128 - Nat Biotechnol. 2013 Jul;31(7):577 – reference: 22517885 - Sci Transl Med. 2012 Apr 18;4(130):130ra48 – reference: 16122423 - Cell. 2005 Aug 26;122(4):553-63 – reference: 16464133 - PLoS Med. 2006 Apr;3(4):e96 – reference: 18951094 - Mol Cell. 2008 Oct 24;32(2):276-84 – reference: 16461460 - Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 – reference: 16258535 - Nature. 2005 Dec 1;438(7068):685-9 – reference: 16483934 - Mol Cell. 2006 Feb 17;21(4):533-42 – reference: 12923253 - RNA. 2003 Sep;9(9):1034-48 – reference: 22052914 - Circ Res. 2012 Jan 6;110(1):71-81 – reference: 16141076 - Science. 2005 Sep 2;309(5740):1577-81 – reference: 16284623 - Nat Cell Biol. 2005 Dec;7(12):1261-6 – reference: 22545703 - Nucleic Acid Ther. 2012 Jun;22(3):152-61 – reference: 23248315 - Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):187-92 – reference: 21900086 - Circulation. 2011 Oct 4;124(14 ):1537-47 – reference: 17676975 - PLoS Biol. 2007 Aug;5(8):e203 – reference: 18403677 - Science. 2008 May 23;320(5879):1077-81 – reference: 12408823 - Mol Cell. 2002 Sep;10(3):549-61 – reference: 20211135 - Cell. 2010 Mar 5;140(5):652-65 – reference: 14973191 - Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 – reference: 17694064 - Nat Methods. 2007 Sep;4(9):721-6 – reference: 16041363 - Nat Biotechnol. 2005 Aug;23(8):1002-7 – reference: 7685712 - FEBS Lett. 1993 Jun 28;325(1-2):123-7 – reference: 21903933 - Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15816-21 – reference: 14976261 - Science. 2004 Mar 5;303(5663):1529-31 – reference: 20173740 - Nat Cell Biol. 2010 Mar;12 (3):247-56 – reference: 19383765 - RNA. 2009 Jun;15(6):1005-11 – reference: 17535905 - Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9667-72 – reference: 10807002 - Biochim Biophys Acta. 1999 Dec 10;1489(1):117-30 – reference: 17363372 - J Biol Chem. 2007 May 11;282(19):14328-36 – reference: 22939619 - Cell. 2012 Aug 31;150(5):895-908 – reference: 17873866 - Nat Biotechnol. 2007 Oct;25(10):1149-57 – reference: 20305636 - Nature. 2010 Apr 15;464(7291):1067-70 – reference: 12022830 - J Am Chem Soc. 2002 May 29;124(21):5974-82 – reference: 17108989 - Nat Chem Biol. 2006 Dec;2(12):711-9 – reference: 21625215 - Oncogene. 2011 Nov 24;30(47):4750-6 – reference: 16756390 - PLoS Biol. 2006 Jul;4(7):e210 – reference: 8252621 - Cell. 1993 Dec 3;75(5):843-54 – reference: 15880588 - Hepatology. 2005 Jun;41(6):1349-56 – reference: 19135890 - Cell. 2009 Jan 9;136(1):75-84 – reference: 7541132 - Nucleic Acids Res. 1995 Jun 11;23(11):2019-24 – reference: 22344686 - Sci Transl Med. 2012 Feb 15;4(121):121ra18 – reference: 10642801 - Dev Biol. 1999 Dec 15;216(2):671-80 – reference: 19965718 - Science. 2010 Jan 8;327(5962):198-201 – reference: 21674040 - PLoS One. 2011;6(6):e20391 – reference: 20461061 - Mol Ther. 2010 Jul;18(7):1357-64 – reference: 17379663 - Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21 – reference: 18239128 - Science. 2008 Feb 1;319(5863):627-30 – reference: 17968323 - Oncogene. 2008 Apr 3;27(15):2128-36 – reference: 22722835 - Nature. 2012 Jun 28;486(7404):541-4 – reference: 18158133 - Methods. 2008 Jan;44(1):55-60 – reference: 20404851 - Nat Immunol. 2010 May;11(5):373-84 – reference: 8252622 - Cell. 1993 Dec 3;75(5):855-62 – reference: 20855538 - RNA. 2010 Nov;16(11):2043-50 – reference: 21423181 - Nat Genet. 2011 Mar 20;43(4):371-8 – reference: 15172979 - Cancer Res. 2004 Jun 1;64(11):3753-6 – reference: 16081698 - Science. 2005 Sep 2;309(5740):1573-6 – reference: 24336348 - Toxicol Sci. 2014 Mar;138(1):234-48 – reference: 9486653 - Nature. 1998 Feb 19;391(6669):806-11 – reference: 15778705 - Nat Biotechnol. 2005 Apr;23(4):457-62 – reference: 20677099 - Curr Opin Mol Ther. 2010 Aug;12(4):478-86 – reference: 22000013 - Cell. 2011 Oct 14;147(2):344-57 – reference: 16565705 - Nature. 2006 May 4;441(7089):111-4 – reference: 17991735 - J Biol Chem. 2008 Jan 11;283(2):1026-33 – reference: 18345015 - Nat Struct Mol Biol. 2008 Apr;15(4):346-53 – reference: 15372042 - Nature. 2004 Sep 16;431(7006):350-5 – reference: 18712719 - Angew Chem Int Ed Engl. 2008;47(39):7482-4 – reference: 19671867 - Clin Cancer Res. 2009 Aug 15;15(16):5073-81 – reference: 18438401 - Nat Biotechnol. 2008 May;26(5):561-9 – reference: 20885409 - Nat Rev Drug Discov. 2010 Oct;9(10):775-89 – reference: 17596868 - Hepatology. 2007 Jul;46(1):84-94 – reference: 24511174 - Adv Drug Deliv Rev. 2012 Dec 1;64(Suppl):353-365 – reference: 18329372 - Cell. 2008 Mar 7;132(5):875-86 – reference: 15538359 - Nature. 2004 Nov 11;432(7014):173-8 – reference: 15973356 - Nature. 2005 Aug 4;436(7051):740-4 – reference: 20085706 - Cell. 2010 Jan 8;140(1):111-22 – reference: 19379126 - Expert Opin Drug Metab Toxicol. 2009 Apr;5(4):381-91 – reference: 18829576 - Cancer Res. 2008 Oct 1;68(19):8164-72 – reference: 18368051 - Nature. 2008 Apr 17;452(7189):896-9 – reference: 15766527 - Cell. 2005 Mar 11;120(5):635-47 – reference: 10706289 - Nature. 2000 Feb 24;403(6772):901-6 – reference: 16306938 - Nature. 2006 Jan 5;439(7072):89-94 – reference: 17384677 - Oncogene. 2007 Sep 6;26(41):6099-105 – reference: 21969601 - Mol Cell Biol. 2011 Dec;31(23):4760-74 – reference: 20527935 - J Am Chem Soc. 2010 Jun 16;132(23):7976-81 – reference: 21749297 - Nucleic Acid Ther. 2011 Jun;21(3):201-14 – reference: 22608085 - Cell. 2012 Jun 22;149(7):1635-46 – reference: 22659608 - Nat Nanotechnol. 2012 Jun 03;7(6):389-93 – reference: 16204072 - Cancer Res. 2005 Oct 1;65(19):8984-92 – reference: 20661255 - Nat Rev Genet. 2010 Sep;11(9):597-610 – reference: 18362929 - Mol Ther. 2008 Apr;16(4):734-40 – reference: 17331257 - BMC Bioinformatics. 2007 Mar 01;8:69 – reference: 19804757 - Cell. 2009 Oct 2;139(1):112-22 – reference: 20098459 - Nat Rev Immunol. 2010 Feb;10(2):111-22 – reference: 15723075 - Nat Med. 2005 Mar;11(3):263-70 – reference: 22009537 - Cancer Res. 2011 Dec 15;71(24):7608-16 – reference: 22304792 - Acc Chem Res. 2012 Jul 17;45(7):1122-31 – reference: 7849490 - Antisense Res Dev. 1994 Fall;4(3):201-6 – reference: 19219043 - Nat Genet. 2009 Mar;41(3):365-70 – reference: 22852836 - Nucleic Acid Ther. 2012 Oct;22(5):344-59 – reference: 14970398 - RNA. 2004 Mar;10(3):544-50 – reference: 23792630 - Nat Biotechnol. 2013 Jul;31(7):638-46 – reference: 21125669 - J Pathol. 2011 Jan;223(2):102-15 – reference: 12930946 - Nucleic Acids Res. 2003 Sep 1;31(17):4973-80 – reference: 17681183 - Gastroenterology. 2007 Aug;133(2):647-58 – reference: 14744438 - Cell. 2004 Jan 23;116(2):281-97 – reference: 18158304 - Nucleic Acids Res. 2008 Mar;36(4):1153-62 – reference: 17182632 - Nucleic Acids Res. 2007;35(2):687-700 – reference: 23080337 - Nat Rev Drug Discov. 2012 Nov;11(11):860-72 – reference: 17379774 - Science. 2007 Apr 27;316(5824):575-9 – reference: 15531877 - Nature. 2004 Nov 11;432(7014):235-40 – reference: 19043405 - Nature. 2008 Dec 18;456(7224):980-4 – reference: 16024602 - Cancer Res. 2005 Jul 15;65(14):6029-33 – reference: 23982190 - Mol Ther Nucleic Acids. 2013 Aug 27;2:e117 – reference: 18691745 - Cell. 2008 Aug 22;134(4):577-86 – reference: 17699775 - Cancer Res. 2007 Aug 15;67(16):7713-22 – reference: 16503100 - Gene. 2006 May 10;372:137-41 – reference: 19748357 - Mol Cell. 2009 Sep 11;35(5):610-25 – reference: 8464037 - J Med Chem. 1993 Apr 2;36(7):831-41 – reference: 21753793 - Gene Ther. 2011 Dec;18(12):1111-20 – reference: 14976262 - Science. 2004 Mar 5;303(5663):1526-9 – reference: 23649362 - Nat Struct Mol Biol. 2013 May;20(5):541-3 – reference: 18758474 - Nat Rev Drug Discov. 2008 Sep;7(9):771-82 – reference: 15520458 - Nucleic Acids Res. 2004 Nov 01;32(19):e149 – reference: 19749770 - Nat Biotechnol. 2009 Oct;27(10):925-32 – reference: 18344688 - Cell Cycle. 2008 Mar 15;7(6):759-64 – reference: 18521080 - Oncogene. 2008 Sep 25;27(43):5651-61 – reference: 20018759 - Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):264-9 – reference: 21212128 - Nucleic Acids Res. 2011 Mar;39(6):e38 – reference: 22351564 - EMBO Mol Med. 2012 Mar;4(3):143-59
SSID	ssj0016172
Score	2.6448975
SecondaryResourceType	review_article
Snippet	Key Points MicroRNAs (miRNAs) have important roles in many aspects of human diseases, and their targeted inhibition may have substantial therapeutic impact.... MicroRNAs (miRNAs) are evolutionarily conserved small non-coding RNAs that have crucial roles in regulating gene expression. Increasing evidence supports a...
SourceID	proquest gale pubmed crossref springer
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	622
SubjectTerms	631/154/51/391/2310 631/337/384/331 692/699/255 692/699/67 692/699/75 Animals Antisense RNA Biomedicine Biotechnology Cancer Research Drug Delivery Systems Drug Discovery Genetic regulation Genetic research Humans Medicinal Chemistry MicroRNAs - biosynthesis MicroRNAs - drug effects MicroRNAs - physiology Molecular Medicine Pharmacology/Toxicology Properties review-article RNA Interference - drug effects RNA Interference - physiology
Title	Therapeutic targeting of microRNAs: current status and future challenges
URI	https://link.springer.com/article/10.1038/nrd4359 https://www.ncbi.nlm.nih.gov/pubmed/25011539 https://www.proquest.com/docview/1550129439 https://www.proquest.com/docview/1551018676
Volume	13
WOSCitedRecordID	wos000340075500018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-1784 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0016172 issn: 1474-1776 databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-1784 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0016172 issn: 1474-1776 databaseCode: 7RV dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-1784 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0016172 issn: 1474-1776 databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9tAEB7aJIde0kfaRG0atlCcS0S62rXW6qW4JSEnY0wafBPSPqDQyollB_LvM7O78iOFXnoRmJ0VI8_sziftzDcAnx0iNlebPJW1xheU3Ni0UPjTmkpVvHCq4M43m1Cj0WA6Lcbxg1sb0yq7PdFv1Gam6Rv5OUFpjE0YP7_d3qXUNYpOV2MLjeewywkboz-ryc3qFIGis68uUjLlSuWhaJYowc-buUGgUGxFo6d78kZQenJK6oPP5cv_VfsV7EfYyYbBT17DM9u8gd448FY_nLHrdRlWe8Z6bLxmtH44gKuNYRZyx1FNNnPsD-XzTUbD9ivTgemJUYnSsmVVY1ggLGG6a9jSvoWflxfXP67S2IIh1YjcFiniP1sJnpm8b6vCFTpDI_adyY2RVa2MlZnLrOTGOilcza3QQtUIQzKHXiCleAc7zayxR8DMF42Cuo_TBP71EndZgW_ygvMaDVFlCfQ6U5Q68pNTm4zfpT8nF4My2iwBthK8DZQcf4ucki1LWqR4D13FWgPUhOiuyiHiFAwRfSUSON6SxMWlt4c7s5Zxcbfl2qYJfFoN00xKWGvsbOlliAstV3kCh8GLVsoi6kQc7md3brVx8-0nef9vBT7AC0RwMmQkHsPOYr60H2FP3y9-tfMTvxroOlX-OjiB3e8Xo_HkEWt0F1A
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VgEQvPAq0hgJbqU0vtVp7N94YCaEIqFK1RBFKpdyMvQ-pUuu0cQLKn-I3MuO182il3nrgaO3sah-z8_DOfAOwa9Fis5mOfJEpdFAibfxY4qfRqUyD2Mo4sGWxCdnrtYfDuL8Gf-tcGAqrrGViKaj1SNE_8kMypVE3of78cn3jU9Uoel2tS2g4tjg1sz_oshWfT77h-e6F4fH3wdeuX1UV8BUaIxMfTRqT8iDUUcuksY1ViPNqWR1pLdJMaiNCGxoRaGMFt1lguOIyQ80aWlyYEBzHfQSPUY5LcvbkcO7gkatQvq4KKfxAysgl6RIE-WE-1miYxCva77YOWFKCt15lS2V3_Px_26YX8Kwyq1nH3YOXsGbyDWj2HS737IANFmlmxQFrsv4CsXv2CrpLzczFxuO2sJFlVxSv-LPXKT4x5ZCsGKVgTQuW5po5QBam6oI0xWs4f5BVvoFGPsrNFjB9pJBQtbAbx6MWqEW4yTgPggwPPg09aNZHn6gKf53KgFwmZRwAbycVj3jA5oTXDnLkLsk-8U5CQgjHUGmVS4EzITivpIN2GKrAluQebK9QovBQq801GyWV8CqSBQ95sDNvpp4UkJeb0bSkIay3SEYebDqunU8WrWr0M8reNRsvDb66krf3T-AjPO0OfpwlZye903ewjtaqcNGX29CYjKfmPTxRvycXxfhDeRMZ_Hponv4HmnFzuw
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LT9wwEB7RBVVcWt5NC8VIsFyIlsTemFSqqi2wAoGiCIHELSR-SEg0Sze7rfav9dd1HCf7AIkbB46Rx5btfJn5HM8DYFcjY9OZDFyWCTygBFK5IcdHJVOeeqHmoafLYhM8io5ub8N4Dv7VsTDGrbLWiaWilj1h_pG3DJVG24T2s6Urt4j4pPvj8bdrKkiZm9a6nIaFyIUa_cXjW_H9_ATf9Z7vd0-vj8_cqsKAK5CYDFykNyqlni-DtkpDHQof59jWMpCSpRmXivnaV8yTSjOqM09RQXmGVtbXuEjGKI77DuY5kgzWgPmfp1F8Nb7DMNygjG3izPU4D2zIrklI3sr7EmlKOGMLn1qEKZP45I62NH3dj29505bgQ0W4Scd-Icswp_IVaMY2Y_fogFxPAtCKA9Ik8SSX92gVzqaaifWaxy0iPU1-GU_Gq6hTfCPC5rgiJjhrWJA0l8SmaiGiLlVTrMHNq6xyHRp5L1efgMhDgYKijd0ovnaG9oWqjFLPyxAEqe9As4ZBIqrM7KZAyENSegjQo6TCiwNkLPhok5E8F9k3OEqMesIxRFpFWeBMTKKvpIMMDY1jm1MHNmckUa2I2eYaUkml1opkgicHdsbNpqdx1ctVb1jKmCxwAQ8c2LAIHk8W-TaeQMreNaSnBp9dyeeXJ7AN7xHKyeV5dPEFFpHGMuuWuQmNQX-otmBB_BncF_2v1WdJ4O61Qf0fBDJ92w
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+targeting+of+microRNAs%3A+current+status+and+future+challenges&rft.jtitle=Nature+reviews.+Drug+discovery&rft.au=Li%2C+Zhonghan&rft.au=Rana%2C+Tariq+M&rft.date=2014-08-01&rft.pub=Nature+Publishing+Group&rft.issn=1474-1776&rft.volume=13&rft.issue=8&rft.spage=622&rft_id=info:doi/10.1038%2Fnrd4359&rft.externalDocID=A381146573
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1474-1776&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1474-1776&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1474-1776&client=summon